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Abstract 
Introduction 
Management of HIV/AIDS has been successful with the use of antiretroviral therapy (ART). 
Consequently, the introduction of highly active antiretroviral therapy (HAART) has further increased the 
life expectancy of people living with HIV/AIDS and this has become a standard regimen in clinical 
practice. However, discordant views have been reported regarding its effects on the kidney; with a dearth 
of literature on the impact of HAART in a diabetic comorbid state on the renal morphology and the 
possible role of plant-based adjuvant. This study investigated the effect of mormodica charantia (M. 
charantia) on the kidney following HAART regimen (triplavar) and its impact in diabetic nephropathy 
(DN) in streptozotocin (STZ) induced diabetic rats. 
Materials and Methods 
78 adult male Sprague-Dawley rats were divided into non-diabetic and diabetic groups.  Rat models of 
diabetes were successfully established by intraperitoneal injection of STZ (45 mg/kg body weight). 
Animals were administered an adjuvant treatment of M. charantia and HAART regimen (triplavar) 
according to protocols. On the 10
th
 week, animals were euthanized with an overdose of halothane and 
kidney tissues were harvested and processed for light microscopy and transmission electron microscopy 
(TEM). Blood samples were obtained via cardiac puncture and centrifuged to collect the serums for 
biochemical analysis. Urine samples were collected at 3weeks interval during the 10 weeks experimental 
period for analysis of renal function test. Body weight and blood glucose levels (BGL) were measured 
once a week during the 10 weeks treatment. 
Results 
In the non-diabetic group, HAART alone treated rats showed renal dysfunction which were characterized 
by raised levels of blood urea nitrogen (BUN) and serum creatinine (Scr), microalbuminuria and gross 
electrolyte disturbances (Sodium and Potassium) as well as urea retention. Also, levels of oxidative stress 
(superoxide dismutase-SOD, catalase-CAT and glutathione peroxidase-GPx) were significantly decreased 
in these groups together with an increased levels of thiobarbituric acid reactive substances (TBARS) 
resulting in free radical formation via auto-oxidation. More so, the histopathological results displayed 
severe glomerular capillary abnormalities with inflammatory cellular infiltrations. This correlated with 
TEM analysis that showed swollen mitochondrial in the endothelium and thickness of the basement 
membrane with overexpression of extracellular matrix. Furthermore, there were upregulation of 
circulating neutrophil gelatinase associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1) and 
tumor necrosis factor-alpha (TNF-α) following HAART alone treatment. 
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In the diabetic groups consistent raised levels of blood glucose which remained peaked from the 5
th
 week 
of experiment were seen in the diabetic control and HAART treated group. There were increased levels of 
both BUN and Scr. Renal function test showed leakage of albumin, retention of renal electrolytes (sodium 
and potassium) and high concentration of urea in the urine of diabetic control and HAART treated group. 
Activities of antioxidative enzymes (SOD, CAT) and levels of GSH were markedly decreased with an 
increased level of Malondiadehyde (MDA). Significant (p<0.05) upregulation of the gene expression 
profiles (NGAL, KIM-1 and TNF- α) were also seen.   
Qualitative light microscopic result using hematoxylin and eosin (H and E) stains showed glomerular 
capillary abnormalities and tubular epithelial damage. These findings correlated with other special stains 
(PAS and MT) which showed high proportion of glycogen, glycoproteins as well as mild deposition of 
collagen fibers and hyaline substances respectively. TEM analysis displayed an abnormally increased 
thickness of basement membrane which reflects the existence of endothelial damage (diabetic control). 
By contrast, following adjuvant treatment with M. charantia, (low and high dose) these abnormalities 
were significantly reduced thus suggesting a protective effect of M. charantia on the kidney.  
Conclusion 
M. charantia extract administration improved blood glucose levels, maintained renal electrolytes (Sodium 
and Potassium), reinstated renal function (BUN and Scr) restored histoarchitectural and ultrastructural 
patterns and prevented DN development in an STZ-induced diabetic rat model.  
Keywords: HAART, Nephrotoxicity, Diabetic nephropathy, TEM, M. charantia, Sprague-Dawley rats, 
Histoarchiteture. 
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Isifingqo (Isizulu Abstract) 
 
Isingeniso 
Ukuphathwa kwegciwane lesandulela ngculazi nengculaza kuye kwaphumelela ngokusetshenziswa kwe-
antiretroviral therapy (ART). Ngenxa yalokho, ukwethulwa kwe-antiretroviral therapy (HAART) 
okwakhulisa kakhulu kuye kwandisa isikhathi sokuphila kwabantu abaphila negciwane lesandulela 
ngculaza nengculaza futhi lokhu sekube ngumgomo ojwayelekile emisebenzini yomtholampilo. Kodwa-
ke, ukubukwa okungahambisani kahle kuye kwabikwa mayelana nemiphumela yaso ezinsoweni; kanye 
nokushisa kwezincwadi emthethweni we-HAART esimweni se-comorbid yesifo sikashukela ku-
morphology ye-renal kanye nendima engenzeka ye-adjuvant esitshalo. Lolu cwaningo luhlolisise 
umphumela we-mormodica charantia (M. charantia) ezinsoweni ezilandela uhlelo lwe-HAART (triplavar) 
kanye nomthelela walo ku-nephropathy yesifo sikashukela (DN) ku-streptozotocin (STZ) ehoxise 
amakhomikhali ayisifo sikashukela. 
Izimpahla nezindlela 
78 Amadoda amadala aseSprague-Dawley ahlukaniswe abe amaqembu angewona wesifo sikashukela 
nesifo sikashukela. Amanothi omuthi wesifo sikashukela asungulwe ngempumelelo ngomjovo we-
intraperitoneal we-STZ (45 mg / kg isisindo somzimba). Izilwane zanikwa ukwelashwa kwe-adjuvant ka-
M. charantia kanye ne-HAART regimen (triplavar) ngokwezinhlelo. Ngeviki le-10, izilwane 
zazixhunyaniswe nokudlula ngokweqile kwama-halothane nama-tissue tissu zavuna futhi zenziwa 
ukukhishwa kwe-microscopy elula kanye ne-transmission electron microscopy (TEM). Ama-sampuli 
wegazi atholakala nge-cardiac puncture futhi ahloswe ngokuyinhloko ukuqoqa izinsimu zokuhlaziywa 
kwamakhemikhali. Amasampula e-urine aqoqwe ngesikhathi sokugcina ama-3weeks ngesikhathi 
samaviki angu-10 wokuhlola ukuhlaziywa kokuhlolwa komsebenzi wezintambo. Isisindo somzimba 
namazinga weglucose wegazi (BGL) kulinganiswa kanye ngesonto phakathi nokuphathwa kwamasonto 
angu-10. 
Imiphumela 
Esikhathini esingeyona isifo sikashukela, ama-HAART kuphela aphathwe amantombazane abonisa 
ukungasebenzi komzimba okwakubonakala ngamazinga aphakanyisiwe wegazi urea nitrogen (BUN) 
kanye ne-serum creatinine (Scr), i-microalbuminuria kanye nokuphazamiseka okukhulu kwe-electrolyte 
(Sodium and Potassium) kanye nokugcinwa kwe-urea. Futhi, amazinga wokucindezeleka okwenziwe nge-
oxidative (superoxide dismutase-SOD, i-catalase-CAT ne-glutathione peroxidase-GPx) yehle kakhulu 
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kulezi ziqhema kanye namazinga okwanda wezinto ze-thiobarbituric acid ezisebenzayo (TBARS) 
eziholela ekubunjweni okukhulu kwamahhala nge-oxidation ngokuzenzakalela. Ngaphezu kwalokho, 
imiphumela ye-histopathological yabonisa ukungavamile okukhulu kwe-capillary glomerular nge-
infiltrations yama-cellarlar inflammatory. Lokhu kuqhathaniswa nokuhlaziywa kwe-TEM okwakubonisa 
i-mitochondrial evuvukale ekupheleni kwe-endothelium kanye nokuqina kwesimbatho sendawo esezansi 
nokugqithisa okukhulu komthamo we-extracellular. Ngaphezu kwalokho, kwakukhona ukuhanjiswa kwe-
neutrophil gelatinase ehlobene ne-lipocalin (NGAL), i-kidney injection molecule 1 (KIM-1) nesifo se-
necrosis factor-alpha (TNF-α) elandela ukwelashwa kwe-HAART kuphela. 
Lezi zinkinga eziphazamisekile ezitholakala emaqenjini angewona wesifo sikashukela ama-rats aphathwe 
nge-HAART kuphela ayekhona kakhulu (i-HAART yodwa + yesifo sikashukela) kanye (namagundane 
angasetshenziswanga nesifo sikashukela). Amazinga aphakanyisiwe egazi egazini elalilokhu evezwe 
kusukela evikini lesihlanu lokuhlolwa aboniswa. Lokhu kuhambisana nokukhubazeka okunamandla 
okwenyuka kwama-renal okwakubonisa amazinga okwandisa kokubili i-BUN kanye ne-Scr 
nokungalingani kwamandla e-electrolyte kanye nokugcinwa kwe-urea ezinso. Imisebenzi ye-enzymes e-
antioxidative (i-SOD, i-CAT ne-GSH) yehla ngokuphawulekayo ngezinga elengeziwe le-peroxidation ye-
lipid. Ukuguqulwa okuphawulekayo kwamaphrofayli angama-gene (NGAL, KIM-1 no-TNF- α) nawo 
atholakale ku-serum elandelayo ukwelashwa (i-HAART yodwa + yesifo sikashukela) kanye 
(namagundane angasetshenziswanga nesifo sikashukela). 
Umphumela omuhle wokukhanya osebenzayo usebenzisa ama-hematoxylin ne-eosin (H and E) amaconsi 
abonisa ukungalingani kwe-capillary kwe-capillary, ukusoka kwe-capillary kanye nokuphazanyiswa 
okuvamile kwamalokisi e-capillary. Ukuvuvukala kwamangqamuzana, umonakalo we-epithelial we-
tubular kanye ne-necrosis eqinile edongeni lwamasongo elibhekene nokusetshenziswa kwe-
hypercellularity nawo waphawula. Lezi zihambisana nezinye izinsizakalo ezikhethekile ezibonisa izinga 
eliphezulu lama-carbohydrate afana ne-glycogen kanye ne-glycoproteins kanye nokufakwa okuncane 
kwamakhofi ama-collagen nama-hyaline. Ukuhlaziywa kwe-TEM kuboniswe ukuqina okwejwayelekile 
kwesimbatho sendawo esezansi kanye nokuvuvukala kwe-mitochondrial okubonisa ukuthi kukhona 
khona umonakalo wokuphela. Ngokuphambene nalokho, ukulandela ukwelashwa kwe-adjuvant no-M. 
charantia, (isilinganiso esincane nesiphakeme) lezi zinto ezingavamile zancishiswa kakhulu. 
Isiphetho 
UMnu charantia ukukhipha ukuphathwa ngcono ama-blood glucose amazinga, i-electrolyte yama-renal (i-
Sodium ne-Potassium) eyabuyiselwayo, yabuyiselwa umsebenzi we-renal (BUN ne-Scr) iphinde 
xviii 
 
ibuyiselwe amakhemikhali akhethekile kanye nezindlela zokuvimbela ukuvimbela ukuthuthukiswa kwe-
DN kwisimo sokulinganisa isifo sikashukela se-STZ. 
Amagama angukhiye: Ukwelashwa kwe-antiretroviral ephezulu, i-Nephrotoxicity, i-nephropathy yesifo 
sikashukela, i-Ultrastructure, M. charantia, amagundane e-Sprague-Dawley. 
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CHAPTER ONE 
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Background   
In 2016, an estimated number of 36.9 million people globally were already living with the Human 
immunodeficiency virus (HIV), and 1.5 million people have died from acquired immune deficiency 
syndrome (AIDS) (UNAIDS, 2016a). Over 12.2% of the South African populations are living with 
HIV/AIDS and also an estimated 280,000 South Africans died of HIV/AIDS. Approximately 2 million 
South Africans are on antiretroviral therapy (HIV/AIDS, 2015, Shisana et al., 2014). While the 
HIV/AIDS pandemic has received tremendous global support in research and treatment evidenced by the 
improved morbidity and mortality, the challenge of the over 2 million people living with HIV/AIDS 
(PLWHA) in South Africa receiving antiretroviral therapy (ART) still remains the issues of drug 
toxicities and side effects (Shisana et al., 2014). 
The introduction of ART for the management of HIV and AIDS significantly increased the life 
expectancy among HIV-infected individuals with unprecedented changes in disease progression and 
mortality (Azu et al., 2014). The U.S Food and Drug Administration (FDA) approved the combination of 
2 or 3 active antiretroviral agents known as highly active antiretroviral therapy (HAART) (Azu et al., 
2014). HAART involves combining two nucleoside reverse transcriptase inhibitors (NRTIs) or a 
combination of one medication from either non- nucleoside reverse transcriptase inhibitors (NNRTIs) or 
protease inhibitors (PIs) class (Azu et al., 2014). This has become a standard regimen for the management 
of HIV positive patients. 
The therapeutic goal of HAART is to achieve and maintain viral suppression and improve the immune 
function of patients. Despite this have diminished the enthusiasm generated by HAART (Jegede et al., 
2017, Hagmann, 2003). The most common and troublesome toxicities of HAART includes 
hepatotoxicity, nephrotoxicity linked to mitochondrial damage and metabolic disorders such as diabetes 
and hypertension (Lee, 2003, Izzedine et al., 2009, Offor et al., 2017b, Yedla et al., 2015). Nephrotoxicity 
is characterized by tubular necrosis with glomerular hypertrophy resulting from mitochondrial 
dysfunction induced by NRTIs since they inhibit nuclear or mitochondrial deoxyribonucleic acid (DNA) 
polymerase from host cell along with inhibition of reverse transcriptase of HIV (Sanz et al., 2018). NRTIs 
affect DNA polymerase of mitochondria with subsequent deficits in mitochondrial DNA encoded 
enzymes of the mitochondrial respiratory chain (Sanz et al., 2018). Additionally, HAART may increase 
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the risk of other metabolic complications such as diabetes mellitus leading to impaired kidney function. 
This has remained a concern for PLWHAs undergoing treatment.  
Diabetes Mellitus (DM)  is considered as one of the five leading causes of death in the world and it is a 
major global health concern with a projected rise in prevalence from 171 million in 2000 and may reach 
366 million in 2030 (Guariguata et al., 2014). Diabetes remains the most common reason for progressing 
to end stage renal diseases. The clinical presentation of antiretroviral-associated diabetes is consistent 
with that of type 2 diabetes (T2DM). Many HIV/AIDS patients receiving HAART become insulin 
resistance and glucose intolerance resulting in them becoming diabetic (Hulgan, 2018, Mutimura et al., 
2007). 
Insulin resistance occurs when normal insulin levels are inadequate to stimulate glucose uptake in the 
insulin-signaling pathway. The insulin resistance manifests as hyperinsulinemia, hyperglycemia, and 
hypertriglyceridemia (Petersen and Shulman, 2018). Both insulin resistance and insulin deficiency plays 
significant role in the pathogenesis of T2DM (Ozougwu et al., 2013). Insulin resistance has been 
described in 61% of patients treated with PIs and impaired glucose intolerance was observed in 35% of 
HIV patients using HAART ( Tsiodras et al., 2000, Brown et al., 2005). NRTIs were found to contribute 
to the disturbance of glucose metabolism (Blümer et al., 2008). Antiretroviral regimens like stavudine, 
didanosine, tenofovir and lamivudine are considered to be most potent to induce DM risk (Calmy et al., 
2007). In clinical studies of HIV-infected human subjects, antiretroviral drugs were shown to acutely 
inhibit insulin-stimulated glucose disposal (Noor et al., 2002, Noor et al., 2006). The effect on glucose 
disposal is both rapid suggesting a direct blockade of glucose uptake through the glucose transporter 
isoform 4 (GLUT4) (Noor et al., 2006). Disturbance in glucose-insulin homeostasis through 
hyperglycemia, insulin resistance, and impaired β-cell function by PIs was reported in animal models also 
(King, 2012, Mastan and Kumar, 2010). The resulting insulin resistance and glucose intolerance may 
predispose to diabetes and further long- term complications of diabetes such as diabetic nephropathy. 
Diabetic nephropathy, which is a microvascular complication of diabetes has generated a lot interest 
lately, due to significantly high mortality rate characterised by molecular, biochemical, structural and 
functional deficits, a complex process leading up to chronic kidney failure in diabetic patients (Gnudi et 
al., 2016, Duran-Salgado and Rubio-Guerra, 2014). Chronic kidney failure is one of the major end-points 
of diabetic nephropathy. In diabetic nephropathy, hyperglycemia adversely alters biochemical and 
molecular characteristics ultimately resulting in structural and functional deficits of the mitochondrial 
leading to endothelial thickening and consequently progresses to arterial hyalinosis of the afferent and 
efferent arterioles and glomerular hyperfiltration (Nishikawa et al., 2015, Gnudi et al., 2016). The 
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underlying pathophysiological processes leading to the biochemical, structural and molecular deficits in 
the kidney of diabetic patients are varied and complex. Some of the identified mechanisms including 
impaired insulin signaling, mitochondrial dysfunction, alteration of glucose utilization and increased fatty 
acid oxidation are known precursors ultimately leading to chronic kidney failure (Gnudi et al., 2016, 
Duran-Salgado and Rubio-Guerra, 2014).   
Hyperglycaemia appears to be an important driver of diabetes-associated kidney diseases through the 
generation of oxidative stress, promoting adverse events in diabetic nephropathy (Miranda-Díaz, 2016 et 
al., Sagoo and Gnudi, 2018). Mitochondrial dysfunction, increased fatty acid oxidation and impaired 
insulin signaling are known contributors to increased oxidative stress found in diabetic nephropathy 
(Giacco and Brownlee, 2010, Vincent et al., 2004). 
Oxidative stress disrupt endothelial homeostasis through apoptosis and increased generation of reactive 
oxygen species (ROS), depletion of scavenger antioxidant enzymes, activation of mononuclear cells, and 
suppression of associated maladaptive signalling cascades (Asmat et al., 2016). These abnormalities 
underline the development of nephrotoxicity and functional deficits associated with diabetic nephropathy. 
It is important to identify potential therapeutic agents that may help in the prevention or halt the 
progression of diabetic nephropathy and nephrotoxicity associated with most antiretroviral therapies. 
Currently, treatment strategies are directed at controlling glycaemia, and glycemic control remains the 
focal target in the treatment of diabetic nephropathy. Antioxidants have been proposed to hold promise as 
adjuvant therapy to the synthetic therapeutic strategies known for glycemic control in the prevention of 
the development and progression of chronic renal failure associated with diabetes mellitus. Furthermore, 
it has been proposed that strategies that either reduce ROS or augment renal antioxidant defence 
mechanisms might possess therapeutic efficacy in improving renal function and alleviating nephrotoxicity 
in diabetes mellitus (Singh et al., 2013). Therefore, compounds with demonstrated antioxidant and 
hypoglycaemic effects may provide potential therapeutic benefits in ameliorating or reversing the diabetic 
nephropathy and nephrotoxicity associated with most antiretroviral regimens.  
Momordica charantia (M. charantia), has been known to possess antioxidant, hypoglycemic, and other 
phytochemical properties. The fruit, stems, leaves and roots of M. charantia have all been used in 
traditional medicine to help treat ailments such as hyperlipidemia, digestive disorders and microbial 
infections amongst the indigenous populations of Asia, South America, India and Southern Africa 
(Ahmad et al., 2016, Raish, 2017).  However, there is dearth of literature on the antidiabetic effects of M. 
charantia on the renal changes of rats induced by streptozotocin following treatment with HAART. Based 
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on this, this work investigates the adjuvant use of M. charantia and antiretroviral therapy in a non-
diabetic and diabetic condition using rodent model.  
1.2 HIV and AIDS  
Human immunodeficiency virus (HIV) is a retrovirus, one of a unique family of viruses that consist of 
genetic material in the form of ribonucleic acid (RNA), surrounded by a lipoprotein envelope (Bates, 
2016).  HIV cannot replicate on its own and instead relies on the mechanisms of the host cell to produce 
new viral particles. HIV infects helper T cells by means of a protein embedded in its envelope called 
gp120. The gp120 protein binds to a molecule called CD4 on the surface of the helper T cell, an event that 
initiates a complex set of reactions that allow the HIV genetic information into the cell (Bates, 2016, 
Skarbinski et al., 2015). 
Entry of HIV into the host cell also requires the participation of a set of cell surface proteins that normally 
serve as receptors for chemokines (hormone-like mediators that attract immune system cells to particular 
sites in the body) (Amini et al., 2018). It appears that the binding of gp120 to CD4 exposes a region of 
gp120 that interacts with the chemokine receptors. This interaction triggers a conformational change that 
exposes a region of the viral envelope protein gp41, which inserts itself into the membrane of the host cell 
so that it bridges the viral envelope and the cell membrane. An additional conformational change in gp41 
pulls these two membranes together, allowing fusion to occur. After fusion the viral genetic information 
can enter the host cell (Amini et al., 2018). See figure 1.1.  
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Figure 1.1: Overview of HIV replication cycle. Source: https://www.niaid.nih.gov/diseases-
conditions/hiv-replication-cycle. Content last reviewed on June 19, 2018.   
The main cellular target of HIV is a special class of white blood cells critical to the immune system 
known as helper T lymphocytes, or helper T cells. Helper T cells are also called CD4+ T cells because 
they have on their surfaces a protein called CD4 (Perreau et al., 2013). Helper T cells play a central role 
in normal immune responses by producing factors that activate virtually all the other immune system 
cells. These include B lymphocytes, which produce antibodies needed to fight infection; cytotoxic T 
lymphocytes, which kill cells infected with a virus; and macrophages and other effector cells, which 
attack invading pathogens (Perreau et al., 2013).  
HIV is the etiological agent of acquired immune deficiency syndrome (AIDS) and is one of the most 
devastating pathogens worldwide. Acquired immunodeficiency syndrome (AIDS) results from the loss of 
most of the helper T cells in the body (Perreau et al., 2013).  AIDS is the final stage of a chronic infection 
with HIV. There are two types of this virus: HIV-1, which is the primary cause of AIDS worldwide, and 
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HIV-2, found mostly in West Africa (Hemelaar, 2012). Once introduced into the body system, HIV enters 
cells of the immune system, especially white blood cells known as T cells. These cells orchestrate a wide 
variety of disease-fighting mechanisms. Particularly vulnerable to HIV attack are specialized "helper" T 
cells known as CD4 cells. When HIV infects a CD4 cell, it commands the genetic tools within the cell to 
manufacture new HIV virus. The newly formed HIV virus then leaves the cell, destroying the CD4 cell in 
the process (Hemelaar, 2012).  No existing medical treatment can completely eradicate HIV from the 
body once it has infected human cells.  The loss of CD4 cells endangers health because these cells help 
other types of immune cells respond to invading organisms.  The average healthy person has over 1,000 
CD4 cells per micro liter of blood. In a person infected with HIV, the virus steadily destroys CD4 cells 
over a period of years, diminishing the cells‘ protective ability and weakening the immune system. When 
the density of CD4 cells drops to 200 cells per micro liter of blood, the infected person becomes 
vulnerable to AIDS-related opportunistic infections which take advantage of the weakened immune 
defenses to cause disease (Perreau et al., 2013, Hemelaar, 2012). 
 
1.2.1 Global Prevalence of HIV and AIDS 
It is estimated that about 36.9 million people are living with the HIV worldwide in 2016, (See Table 1.1) 
and an estimated 1.5 million people have died from acquired immune deficiency syndrome (AIDS) since 
the first cases were reported in 1980s. Most of these deaths are due to inadequate access to HIV 
prevention, care and treatment services (UNAIDS, 2016a, UNAIDS, 2016b). Adolescents aged between 
15 to 49 years account for an estimated 12 per cent of HIV infections globally (UNAIDS, 2016b). Since 
its discovery in 1983, the infection has quickly developed into a worldwide epidemic, affecting virtually 
every nation. In 1999, about 26.2 million people were living with the virus. By the end of 2009, it was 
estimated that 33.3 million people were living with the disease, corresponding to a 27%. By 2005, more 
than 1.2 million people had died of HIV and AIDS related diseases (WHO and UNICEF, 2013). 
More than two-thirds of HIV infections, roughly 24.7 million persons, were in Sub-Saharan Africa which 
also accounted for close to 80% of women and 90% of children living with HIV (De Cock et al., 2012). 
Asia and the Pacific accounted for approximately 4.8 million HIV infected persons, Western and Central 
Europe and North America, accounted for 2.3 million, (Table1.1). Despite the decline in the new 
infections, South Africa, in the Sub-Saharan Africa region, still bears the highest burden of HIV epidemic 
globally (Poku, 2017). These are staggering data that impacts negatively on the socio-economic indices in 
these countries. 
 
7 
 
Table 1.1: Prevalence of HIV infection and estimated death rates by regions of the world (Ages 15-49). 
World Region Prevalence of HIV 
infection 
Estimated death 
rates 
Prevalence Rate (%) 
Global Total 36.9 million 1.5 million 0.8 
Sub-Saharan Africa 24.7 million 1.1 million 4.7 
Asia and the Pacific 4.8 million 250000 0.2 
Western and Central Europe 
and North America 
2.3 million 27000 0.3 
Latin America 1.6 million 47000 0.4 
Eastern Europe and Central 
Asia 
1.1 million 53000 0.6 
Caribbean 250,000 11000 1.1 
Middle East and North 
Africa 
230,000 15000 0.1 
 
Source:  UNAIDS, 2016a. Global AIDS update 2016. Geneva, Switzerland: World Health Organization 
Library (UNAIDS, 2016a) 
 
1.2.2 Prevalence of HIV and AIDS in Africa 
The HIV pandemic has continued to challenge the development and economy of many countries in Africa 
and has overwhelmed the health-care systems, increased the number of orphans and caused life 
expectancy to reduce. It is one of the public health issues threatening the survival of millions of infected 
people in sub-Saharan Africa (Poku, 2017). 
Its impact has been most severe in some of the poorest countries in Africa. At the end of 2009, there 
were 9 countries in Africa where more than one tenth of the adult population aged 15-49 years was 
infected with HIV (Youde, 2016).  For instance, in some countries in the southern part of the continent, 
including Botswana, Lesotho, Swaziland, Zimbabwe and South Africa, about 30 percent of the 
populations have HIV infection or AIDS (Poku, 2017).  In Kenya, about 2.3 million people live with 
HIV/AIDS and each year, approximately 200,000 Kenyans develop the AIDS syndrome (Luginaah et al., 
2005). 
HIV/AIDS pandemic affect all regions and communities and it impacts negatively on households and the 
economic growth of nations. Sub-Saharan Africa is more heavily affected by HIV/AIDS than any other 
region of the world. In 2008, it was home to two thirds (60%) of all PLWHAs and nearly three quarters 
(72%) of AIDS-related deaths occurs in this region (Kalipeni et al., 2004).  It has ‗sapped‘ the population 
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of young men and women in their productive years who form the foundation of the labor force (Morrell et 
al., 2009). Health care problems have already reached crisis proportions in some parts of the world 
already burdened by war, political upheaval, or unrelenting poverty. 
1.2.3 Prevalence of HIV and AIDS in South Africa 
The toll of HIV/AIDS continues to be harsh in South Africa. In 2013, the country accounted for the vast 
majority of people living with AIDS (Johnson et al., 2017).  In 2017, it is estimated that 12.2% of the 
South Africa's population of 54.95 million had HIV/AIDS. The rising prevalence rate increased from 
10.6% in 2007 to 12% in 2008, and in 2010, an estimated 280,000 South Africans died of HIV/AIDS 
(Atujuna et al., 2018). The Human Sciences Research Council, a South African institution, estimates that 
between 42% and 47% of all deaths among South Africans were caused by HIV/AIDS (Angotti et al., 
2018).  Currently, approximately 6.1 million South Africans are living with HIV/AIDS with over 2 
million on antiretroviral treatment (Shisana et al., 2014). Provincial data on HIV prevalence is shown in 
table 1.2 below. The results show substantial variation of HIV prevalence by province; KwaZulu-Natal 
continues to lead South Africa in HIV prevalence. In most provinces, HIV prevalence in women; aged 15 
years and above, remains significantly higher than in men (Shisana et al., 2014). See table 1.2 
 
Table 1.2: Overall HIV Prevalence by Province in South Africa 
Province Prevalence Rate (%) 
KwaZulu-Natal 16.9 
Mpumalanga 14.1 
Free State 14.0 
North West 13.3 
Gauteng 12.4 
Eastern Cape 11.6 
Limpopo 9.2 
Northern Cape 7.4 
Western Cape 5.0 
Source: Shisana et al., 2014 
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1.2.4 Management of HIV and AIDS 
Whereas no medical treatment can cure AIDS, ART was developed for the management of HIV and 
AIDS to reduce viral load and thus improve longevity. The primary goal of ART is suppression of plasma 
viral load, preservation and restoration of immunologic function, improvement of quality of life and 
reduction of HIV related morbidity and mortality (Fourie, 2006). Early in the 1980s when the HIV/AIDS 
epidemic began with no visible medical therapy known to reduce viremia, people with AIDS were not 
likely to live longer than a few years (Fourie, 2006).  UNAIDS estimated that a total of 2.5 million deaths 
have been averted in low and middle-income countries since 1995 due to the roll out of antiretroviral 
therapy (HIV/AIDS, 2013). In other words, HIV/AIDS is no longer a ‗death penalty‘ for victims. 
The therapy entails the use of antiretroviral medications that attack the virus itself plus other non-
antiretroviral medications to prevent and treat opportunistic infections (OIs) that can occur when the 
immune system is compromised by the virus (WHO and UNICEF, 2009). Counseling and support 
mechanisms are also done to help infected people deal with emotional and traumatizing repercussions by 
encouraging them to accept living with a disabling and potentially fatal disease. This has proven to unlock 
the declines in transmission of the virus (WHO and UNICEF, 2009). 
ART consists of drugs from five classes; they are nucleoside reverse transcriptase inhibitors (NRTIs), 
non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion or entry 
inhibitors and integrase inhibitors which are approved by the United States of America Food and Drug 
Administration (FDA) (FDA, 2012). Table 1.3 shows the various classes of antiretroviral drugs approved 
by the FDA. 
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Table 1.3: Classification of antiretroviral drugs in use. 
Drug Class Mechanism of action Generic Name  
(Other names and 
acronyms) 
Brand Name FDA 
Approval 
Date 
Manufacturers 
name 
Nucleoside 
Reverse 
Transcriptase 
Inhibitors 
(NRTIs) 
Inhibit reverse 
transcription by being 
incorporated into the 
newly synthesized 
viral DNA and 
preventing its further 
elongation. 
 
 
 
 
 
 
  
Abacavir (ABC) Ziagen  December 
17, 1998 
GlaxoSmithKline 
Didanosine  
(ddI, ddI EC) 
Videx October 9, 
1991  
Bristol Myers-
Squibb 
Videx EC 
(enteric-
coated) 
October 31, 
2000 
Bristol Myers-
Squibb 
Emtricitabine  
(FTC) 
Emtriva  July 2, 2003 Gilead Sciences 
Lamivudine  
(3TC) 
Epivir November 
17, 1995 
GlaxoSmithKline 
Stavudine  
(d4T) 
Zerit June 24, 
1994 
Bristol Myers-
Squibb 
Tenofovir disoproxil  
fumarate  
(TDF)  
Viread October 26, 
2001 
Gilead Sciences 
Zidovudine  
(ZDV) 
Retrovir March 19, 
1987 
GlaxoSmithKline 
Non-Nucleoside 
Reverse 
Transcriptase 
Inhibitors 
(NNRTIs) 
Inhibit reverse 
transcriptase directly 
by binding to the 
enzyme and 
interfering with its 
function. 
 
Delavirdine  
(DLV) 
Rescriptor April 4, 1997 Pfizer 
Efavirenz (EFV) Sustiva September 
17, 1998 
Bristol Myers-
Squibb 
Etravirine  
(ETR) 
Intelence January 18, 
2008 
Tibotec 
Therapeutics 
Nevirapine  
(NVP) 
Viramune  
(Immediate 
Release) 
June 21, 
1996 
Boehringer 
Ingelheim 
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Viramune XR 
(Extended 
Release) 
March 25, 
2011 
Boehringer 
Ingelheim 
Rilpivirine  
(RPV) 
Edurant May 20, 
2011 
Tibotec 
Therapeutics 
Protease 
Inhibitors (PIs) 
Target viral assembly 
by inhibiting protease 
enzyme used by HIV 
to cleave nascent 
proteins for final 
assembly of new 
virons. 
 
Atazanavir  
(ATV) 
Reyataz June 20, 
2003 
Bristol-Myers 
Squibb 
Darunavir  
(DRV) 
Prezista June 23, 
2006 
Tibotec, Inc. 
Fosamprenavir 
(FPV) 
Lexiva October 20, 
2003 
GlaxoSmithKline 
Indinavir  
(IDV) 
Crixivan  March 13, 
1996 
Merck 
Nelfinavir  
(NFV) 
Viracept March 14, 
1997 
Agouron 
Pharmaceuticals 
Ritonavir  
(RTV) 
Norvir March 1, 
1996 
Abbott 
Laboratories 
Saquinavir  
(SQV) 
Invirase December 6, 
1995 
Hoffmann-La 
Roche 
Tipranavir  
(TPV) 
Aptivus June 22, 
2005 
Boehringer 
Ingelheim 
Fusion or entry 
Inhibitors 
Prevent HIV from 
binding to or entering 
human immune cells. 
 
Enfuvirtide (T-20) Fuzeon March 
13,2003 
Hoffmann-La 
Roche & 
Trimeris 
Maraviroc  
(MVC) 
Selzentry August 6, 
2007 
Pfizer 
Integrase 
Inhibitors 
Inhibit integrase 
enzyme needed by 
HIV to insert its 
genetic material into 
human cells. 
 
Dolutegravir  
(DTG)  
Tivicay August 13, 
2013  
GlaxoSmithKline 
Elvitegravir 
(EVG) 
Vitekta September 
24, 2014 
Gilead Sciences 
Raltegravir  
(RAL) 
Isentress October 12, 
2007 
Merck & Co., 
Inc. 
Source: https://aidsinfo.nih.gov/understanding-hiv-aids/fact.../21/.../fda-approved-hiv-medicine. Last 
reviewed: June 24, 2019 
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1.3 Highly Active Antiretroviral Therapy 
Reports from clinical trials are indicating that single therapies are not completely effective in combating 
HIV virulence and this is the basis for the introduction of combination antiretroviral therapy, mostly 
called highly active antiretroviral therapy (HAART) (See Table 1.4) (Sendi et al., 2001).  HAART has 
been effective in suppressing the viral load to undetectable levels resulting in decreased HIV RNA levels 
and CD4 T cell increases in the vast majority of patients (Andrade et al., 2017, Viswanathan et al., 2015). 
HAART has dramatically decreased the number of hospital admissions and PLWHA have achieved an 
impressive improvement in the quality of life (Andrade et al., 2017). Many people affected by the virus 
are now living with a manageable chronic condition. With increasing global awareness campaign and 
continuous roll out of HAART coupled with effective prophylaxis for opportunistic infections, the 
number of infection and HIV mortality rates has dramatically declined (Viswanathan et al., 2015, WHO 
and UNICEF, 2013). 
Table 1.4: Possible combination antiretroviral therapy- FDA approved. 
Drug Class Generic Name  
(Other names and 
acronyms) 
Brand Name FDA Approval 
Date 
Manufacturers 
name 
Multi class 
combination 
products 
Lamivudine, 
Zidovudine and 
Nevirapine 
(3TC,/ZDV, NVP) 
Triplavar September 12, 
2017 
Cipla Medpro 
Abacavir and 
Lamivudine  
(ABC / 3TC) 
Epzicom August 2, 2004 GlaxoSmithKline 
Abacavir, 
Dolutegravir, and 
Lamivudine 
(ABC / DTG / 3TC)  
Triumeq  August 22, 2014 ViiV Health care 
and Shionogi & 
Co Ltd. 
Abacavir, 
Lamivudine, and 
Zidovudine 
(ABC / 3TC / ZDV) 
Trizivir November 14, 
2000 
GlaxoSmithKline 
Atazanavir and Evotaz
 
January 29, Bristol-Myers 
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Cobicistat 
(ATV / COBI) 
2015 Squibb 
Darunavir and 
Cobicistat 
(DRV / COBI) 
Prezcobix
 
January 29, 
2015 
Jassen 
Therapeutics 
Efavirenz, 
Emtricitabine, and 
Tenofovir disoproxil 
fumarate 
( EFV / FTC / TDF) 
Atripla July 12, 2006 Bristol-Myers 
Squibb and Gilead 
Sciences 
Elvitegravir, 
Cobicistat, 
Emtricitabine, and 
Tenofovir disoproxil 
fumarate 
(EVG / COBI / FTC 
/ TDF) 
Stribild August 27, 2012 Gilead Sciences 
Emtricitabine, 
Rilpivirine, and 
Tenofovir disoproxil 
fumarate 
(FTC / RPV / TDF) 
Complera August 10, 2011 Gilead Sciences 
Emtricitabine and 
Tenofovir disoproxil 
fumarate 
(FTC / TDF) 
Truvada August 2, 2004 Gilead Sciences, 
Inc. 
Lamivudine 
and zidovudine 
(3TC / ZDV) 
Combivir  September 27, 
1997 
GlaxoSmithKline 
Lopinavir and 
Ritonavir 
(LPV / RTV) 
Kaletra September 15, 
2000 
Abbott 
Laboratories 
Source: https://aidsinfo.nih.gov/education.../fact.../fda-approved-hiv-medicines. Last reviewed: June 24, 
2019 
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1.3.1 HAART- related side effects 
Reduction in morbidity and mortality has been the most outstanding achievement in the global fight 
against HIV/AIDS in both low and middle-income countries, but despite this achievement, there are 
concerns about associated side effects of HAART, which have increased more recently (Viswanathan et 
al., 2015, Subbaraman et al., 2007). HAART- related side effects may be transient or may persist 
throughout therapy, and have been attributed to severe deleterious consequences mediated through 
different pathophysiological pathways and eventually a major reason for the discontinuation of therapy or 
change in treatment strategy, thereby limiting patients adherence and consequently, virologic 
effectiveness (Cihlar and Fordyce, 2016). 
Each drug in the HAART combination has its own side effects; however, the three common side effects 
of HAART are diarrhea, nausea and fatigue (Carr and Cooper, 2000). Toxicities like lactic acidosis, 
hepatic steatosis, progressive neuromuscular weakness, dyslipidemia and lipodystrophy also occurs after 
the drugs had been in use for years (Manfredi and Chiodo, 2001). Other increasing side effects caused by 
HAART ranges from mild to severe organ toxicity such as hepatotoxicity, testicular injury, nephrotoxicity 
and many others of which have been well documented in several studies (Mocroft et al., 2005). 
1.3.2 HAART-related kidney Injury 
The kidneys have important physiological functions including maintenance of water and electrolyte 
balance, secretion of hormones and excretion of waste products from the body. In addition, the kidneys 
plays an important role in the metabolism and excretion of drugs and hence may be exposed to high 
concentrations of drug metabolites making it liable to drug toxicity such as acute kidney injury (AKI), 
tubulopathies, chronic kidney disease (CKD) and end-stage renal disease that may often require renal 
replacement therapy (Pannu and Nadim, 2008, Tiwari et al., 2018).  It is therefore not a surprise that drug-
induced kidney injuries contribute up to 25% of all cases of acute renal failure (Pannu and Nadim, 2008). 
Drug-induced kidney injuries may cause cumulative dose-dependent toxicity or idiosyncratic dose-
independent toxicity at any time during therapy (Pannu and Nadim, 2008). Renal injury may occur in 
various renal compartments such as the renal vascular supply, the glomerulus, the collecting ducts, the 
tubulointerstitium where extensive tubular-peritubular capillary exchange of solutes takes place 
(Humphreys, 2018). 
Clinically, HAART causes various kidney injuries including various electrolyte and acid-base disorders 
as well as lactic acidosis. These injuries occur via mechanisms such as direct tubular toxicity, allergic 
reactions and precipitation of insoluble drug crystals within renal tubular lumens (Yedla et al., 2015). 
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HAART nephrotoxic effects accounted for 14% of late-onset of AKI episodes, occurring 3 months 
after initiating HAART (Mehdi et al., 2016). Combined therapy with tenofovir disoproxil fumarate 
(TDF) and protease inhibitors (PIs) such as ritonavir appears to increase renal toxicity, severe 
immunosuppression (CD4 count, <200 cells/mm3) and opportunistic infections (LaFleur et al., 2018). 
Approximately, 70% of the published cases of TDF-induced nephrotoxic effects are observed with 
concomitant use with ritonavir (LaFleur et al., 2018).  
An interaction between lopinavir- ritonavir combination therapy and TDF, which manifests as a decrease 
in the renal clearance of TDF, has been identified (Jotwani et al., 2016).  A recent study by the Columbia 
University group demonstrated that TDF nephrotoxicity is manifested as toxic acute tubular necrosis 
targeting proximal tubules and manifests in distinctive light microscopic and ultra-structural features of 
mitochondrial injury (Offor, 2015, Kalyesubula and Perazella, 2011). Exposure to TDF showed adverse 
serious renal events and graded elevations in serum creatinine of patients, and it has also been linked to 
the development of proximal tubular dysfunction including Fanconi syndrome (FS), AKI, nephrogenic 
diabetes insipidus (NDI), and severe hypokalemia (Kalyesubula and Perazella, 2011). FS caused by 
tenofovir-induced nephrotoxicity is characterized by generalized proximal tubular dysfunction resulting in 
glycosuria, phosphaturia, uricosuria, aminoaciduria, and tubular proteinuria (Fernandez-Fernandez et al., 
2011, Elias et al., 2014). Lamivudine, stavudine, abacavir and didanosine have also been implicated in 
case reports of FS and NDI (Kalyesubula and Perazella, 2011, Izzedine et al., 2004). Acute interstitial 
nephritis (AIN), impaired kidney function and hyperlactemia have all been implicated with classes of 
nucleoside reverse transcriptase inhibitors (NRTIs) and  non- nucleoside reverse transcriptase inhibitors 
(NNRTIs) and increased the propensity of leading to chronic kidney disease (Perazella and Markowitz, 
2010, Kalyesubula and Perazella, 2011). 
1.3.3 HAART- related comorbid conditions 
Many patients taking HAART achieve a complete lifelong virologic suppression, and thus, AIDS-related 
conditions are becoming less common, with a dramatic drop in overall morbidity and mortality. However, 
despite the apparently full control of HIV infection by HAART, clinical evidence has demonstrated that 
HAART does not completely restore health in HIV-infected patients, who are affected by an increased 
risk of several non-AIDS complications, also known as comorbid conditions (Gazzola et al., 2010, Pallela 
et al., 1998). The HAART-related comorbid conditions are many and includes metabolic abnormalities 
such as; dyslipidemia, high blood pressure or hypertension, cardiovascular diseases, lipodystrophy, 
glucose intolerance and insulin resistance, these abnormalities are together referred to as metabolic 
syndromes (Gazzola et al., 2010). 
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The potential long-term consequences of HAART-associated dyslipidemia are not completely understood, 
several pathophysiological ways have revealed that dyslipidemia in HIV-infected patients involves 
interactions between the virus and antiretroviral therapies and host factors. (Green, 2002, Mooser and 
Carrr 2001).  
Dyslipidemia is characterized by hypertriglyceridemia and hypercholesterolemia which are features of 
defective lipoprotein metabolism. Although abnormal lipid profiles are reported in HIV infected 
individuals before the onset of HAART, however, hypertriglyceridemia and hypercholesterolemia 
becomes both more prevalent and severe during treatment with HAART (Feeney and Mallon, 2011, Van 
Wijk and Cabezas, 2012). According to Calza et al., dyslipidemia occurs in up 70%-80% of HIV- infected 
individuals receiving HAART and can be associated with the entire available PIs (Calza et al., 2004, 
Calza et al., 2016).  As a result, risk factors for long-term adverse effects have become increasingly 
important in therapeutic decisions regarding HIV/AIDS patient care. 
Reduction in mortality rate as a result of antiretroviral therapy in HIV/AIDS population comes with 
increased significance of other risk factors such as cardiovascular diseases. Compelling evidence suggests 
that HIV/AIDS patient is at an increased risk for atherosclerotic cardiovascular disease. This appears to 
promote atherogenesis by sensitizing the arterial wall to various pathological processes (Dimala and 
Blencowe, 2017, Dimala et al., 2016b, Zanetti et al., 2018).  
The role of inflammation in the pathologic process of atherogenesis has been established.  The initiation 
of fatty streaks, the precursors of atheromatous plaques, is now known to be mediated by an inflammatory 
response with the migration of monocytes into the subintimal space of the artery. The inflammatory 
response results form a cascade of events triggered by noxious stimuli to the endothelium of the artery. 
This consequently leads to atherosclerotic cardiovascular disease (Libby et al., 2013, Gerszten et al., 
1999). 
With a heightened attention of cardiovascular disease associated with antiretroviral therapy, management 
of HIV and AIDs has now become a double edge sword. Although it is likely that cardiovascular disease 
risk in the HIV patients may be accounted for by other pathological conditions linked to HIV infection in 
interaction with mediating processes such as inflammatory cytokines, it appears that protease inhibitors 
and NNRTIs medications may exacerbate the cardiovascular disease to enhance the risk. This is 
particularly relevant in North America and Europe, where an increasing portion of the HIV-infected 
population comprises middle-aged men, and receiving treatment with PIs, shows significant development 
of cardiovascular disease (Dimala et al., 2016b, Dimala and Blencowe, 2017). 
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There is also compelling evidence that hypertension is an important risk factor for cardiovascular disease 
and it is a multifactorial disease arising from the combined action of many environmental, behavioral and 
genetic variants especially in PLWHAs, as well as oxidative stress and inflammation which may result 
from drug use (Dimala et al., 2016b, Lombo et al., 2015). Literature reveal  an increasing frequency of 
hypertension among HIV-infected patients on HAART especially in combinations which includes 
Protease Inhibitors (PI) (Seaberg et al., 2005).
 
In countries with unlimited access or delayed roll-out of HAART, HAART-associated cardiovascular 
disease and hypertension has become one of the major causes of death. The pathogenesis of hypertension 
is clearly complex. The pathophysiology usually involves increase in cytokines release which will induce 
imbalance of the endothelium and endogenous vasodilators and constrictors (Bigna et al., 2015) . While a 
portion of this risk appears to be related to antiretroviral therapy, there is also evidence that traditional 
history of cardiac risk factors could play a role in the development of hypertension and other 
cardiovascular diseases in PLWHA. Therefore, management of cardiac risk will be important in the 
treatment of HIV/AIDS.  
With the recent advances in antiretroviral therapy, management of HIV/AIDS infection has also become 
an important consideration for the development of other complications such as lipodystrophy.  
Lipodystrophy which includes both lipoatrophy and lipohypertrophy are common in HIV-infected 
participants and typically start to manifest after 6–12 months of HAART therapy (Cerrato et al., 2015). 
Lipoatrophy denotes a decrease in adipose tissue volume while lipohypertrophy denotes the opposite, and 
it commonly occurs in visceral adipose tissue and in the upper trunk. This unsual fat redistribution has an 
implication in the body physiology and anatomy which may eventually lead to CVD risk  (Cerrato et al., 
2015, Pereira et al., 2015). 
The HAART associated lipodystrophy is multi-factorial in etiology, affecting both lipid/glucose 
metabolism and insulin sensitivity, altering the activity of glucocorticoid receptors in several tissues 
(Cerrato et al., 2015).  Fat redistribution may also promote insulin resistance and impaired glucose 
tolerance through altered secretion of adipokines and other inflammatory markers (such as ILs 6, 8 and 
10, and macrophage chemotactic protein-1) (Gustafson et al., 2015).  Impaired glucose tolerance (IGT) is 
a pre-diabetic state of dysglycemia that is associated with insulin resistance and increased risk of 
cardiovascular pathology. Impaired glucose tolerance and diabetes mellitus can occur in HIV patients 
receiving HAART through various pathophysiological mechanisms.  
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1.4 Diabetes Mellitus 
Diabetes mellitus (DM) is a group of chronic disorders of carbohydrate, proteins and fat metabolism 
characterized by hyperglycemia arising from defects in insulin secretion, insulin action or both 
(Association, 2013). Two major types of diabetes mellitus are recognized on the basis of absolute or 
relative deficiency of insulin (Table 1.5).  DM associated with absolute insulin deficiency (Type I DM or 
T1DM) has previously been described with terms such as Insulin Dependent Diabetes Mellitus (IDDM) 
or juvenile onset diabetes mellitus. TIDM is an autoimmune disease triggered by environmental factors in 
genetically susceptible individuals and its pathogenesis is characterized by destruction of beta cells of the 
islets of the pancreas, thus making them dependent on exogenous insulin (Atkinson et al., 2014). (Type II 
DM or T2DM) on the other hand is associated with relative deficiency of insulin, either due to insufficient 
amount (defect in secretion) or insulin resistance (defect in insulin action) even in presence of sufficient 
insulin levels. It was previously referred to as Non-Insulin Dependent Diabetes Mellitus (NIDDM) 
(Atkinson et al., 2014).  
Apart from these major types of diabetes mellitus, other recognized types of diabetes include Maturity 
Onset Diabetes of the Young (MODY), an autosomal dominant genetic defect of β-cell function 
characterized by early onset of hyperglycemia by the age of 25 years due to an impairment of insulin 
secretion with minimal or no loss of insulin action (Asmat et al., 2016). Others include gestational 
diabetes mellitus; a condition defined by presence of impaired glucose tolerance in pregnancy and has 
been associated with increased incidence of complications in pregnancy including intra-uterine fetal death 
(IUFD), stillbirths and macrosomic babies (Asmat et al., 2016). 
Recently, type 3 diabetes mellitus (T3DM) was described, it is characterized by brain tissue resistance to 
insulin action, histopathological, molecular and biochemical features of Alzheimer‘s disease and good 
responses to insulin sensitizers (Kandimalla et al., 2017, Suzanne, 2014). 
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Table 1.5: Classification of Diabetes Mellitus 
 Class of Diabetes Mellitus Mechanism of Diabetes Development 
1. Type 1 Diabetes Mellitus Pancreatic beta-islet cell destruction;  Absolute 
insulin deficiency 
2. Type 2 Diabetes Mellitus Insulin resistance (obesity), relative insulin 
deficiency 
3. Gestational Diabetes Insulin resistance  
4. Others A. Genetic defects in B-cell dysfunction 
B. Genetic defects in Insulin action 
C. Disease of exocrine pancreas 
D. Endocrinopathies 
E. Drugs or chemical Induced 
F. Infection 
G. Immune mediated defects 
H. Genetic syndromes associated with DM 
Source:  Adapted from the report of the expert committee on the diagnosis and classification of diabetes 
mellitus. Diabetes care, 1997; 20: 1183-1197. 
 
1.4.1 Epidemiology of Diabetes Mellitus 
Human, social and economic costs imposed globally by diabetes are enormous, and this is as a result of 
the increasing incidence and prevalence of diabetes world-wide. Currently, 382 million adults have 
diabetes mellitus and a further 361 million are estimated to have impaired glucose tolerance. By 2035, it 
is estimated that 471 million adults will have diabetes mellitus (Meijnikman et al., 2016, Cos et al., 2015). 
The prevalence of diabetes mellitus which stood at 4% globally in 1995 has dramatically risen in less than 
two decades to 8.3 % in 2013 and is expected to rise further in the years to come (Shaw et al., 2010). The 
majority of the 382 million people with diabetes mellitus are between the ages of 40-59 and greater than 
75% of these live in low- and middle-income countries (Meijnikman et al., 2016). T2DM accounts for 90-
95% of all diabetes cases while TIDM accounts for only 5-10% (Dabelea et al., 2014). The prevalence 
rate of diabetes in Africa is expected to rise from 3.8% in 2013 to 4.7 % by the year 2035 (Guariguata et 
al., 2014). In South Africa, it is estimated that about 10 million people aged between 20-79 years have 
one form of diabetes or the other with a prevalence rate ranging between 9-12 % and this is expected to 
rise significantly in the future (Guariguata et al., 2014). 
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1.4.2 Clinical features of Diabetes Mellitus 
DM is a multi-systemic disease with biochemical and structural consequences.  The pathological hallmark 
of DM is marked hyperglycemia which is responsible for most of the symptoms and complications. DM 
classically presents with symptoms including polyuria, polydipsia, polyphagia, weight loss (cachexia), 
fatigue, nausea and blurred vision (Figure 1.2) (Association, 2014). Hyperglycemia by increasing the 
plasma osmolality leads to dehydration that fuels increased water intake. Furthermore, excess circulating 
glucose predisposes to increased glomerular filtration of glucose resulting in glycosuria and further fluid 
loss worsening dehydration and contributing to weight loss (Guariguata et al., 2014).  In TIDM there is 
increased catabolic activity characterized by increased ketosis, hyperglucagonemia, protein catabolism to 
generate precursors needed in gluconeogenesis, and increased lipolysis which also explains weight loss 
observed in diabetic patients (Katsarou et al., 2017).  In humans, TIDM can occur at any age but it is most 
common in the young (juveniles) although adults in their third and fourth decades of life are also at risk 
(Katsarou et al., 2017). TIDM unlike T2DM is not associated with obesity and is commonly diagnosed 
for the first time in patients with diabetic ketoacidosis due to their dependency on exogenous insulin for 
survival (Katsarou et al., 2017). 
 
         
Figure 1.2: Schematic representation of major symptoms of diabetes mellitus.  
 
 
 
 
Excessive Thirst (Polydypsia) 
increased diuresis (Polyuria) 
increased urinary glucose (Glycosuria)  
Hyperglycemia 
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1.4.3 Diagnosis of Diabetes Mellitus 
Diagnosis of diabetes mellitus is based on blood glucose criteria, and two tests most often indicated are 
Fasting Plasma Glucose (FPG) and or 2-hour postprandial plasma glucose levels (2-HRPP) after glucose 
load in the Oral Glucose Tolerance Test (OGTT) (Association, 2017). Designated diagnostic cut off 
points of FPG values ≥7.0 mmol/l  or 2-HRPP values ≥11.1mmol/l after a 75-g oral glucose or random 
plasma glucose ≥11.1mmol/l in an individual with classic symptoms of hyperglycemia or hyperglycemic 
crisis are regarded as diabetic (See Table 1.6) (Association, 2017). The International Expert Committee 
appointed by American Diabetic Association, European Association for the Study of Diabetes and 
International Diabetes Association recommend plasma HbA1c assay as a diagnostic method in individuals 
without classic symptoms of TIDM (Association, 2017). 
Table 1.6: Diagnostic Criteria for Diabetes Mellitus 
Stage                        Diagnostic Test  
 Fasting Blood Glucose (FBG) 2-Hour Glucose Tolerance 
Test (GTT) 
Normal            <6.1 mmol/l < 7.8 mmol/l 
Pre-diabetes mellitus         ≥ 6.1 mmol/L and < 7.0      
mmol/l 
 ≥ 7.8 mmol/L and< 11.1 
mmol/l 
Diabetes Mellitus           ≥ 7.0 mmol/l ≥ 11.1 mmol/l 
Source: Adapted from the diagnosis and classification of diabetes mellitus. Diabetes care; 33: Suppl. 1: 
S62-S69. The report of the expert committee on the diagnosis and classification of diabetes mellitus. 
Diabetic care 2004; 27: S1-10. 
1.4.4 Insulin synthesis and secretion  
Insulin deficiency is the characteristic hallmark of TIDM and is responsible for the marked 
hyperglycemia that is central to the pathophysiology, clinical features and complications of TIDM (Kent 
et al., 2015). Insulin is a polypeptide hormone produced by the beta-islet cells of the pancreas, its 
deficiency in TIDM leads to increased gluconeogenesis and ketogenesis by the liver resulting in severe 
hyperglycaemia and hyperketonemia  (Ali et al., 2017).  Insulin is synthesized from amino acid precursors 
as pre-proinsulin which undergoes several enzymatic cleavages to yield pro-insulin (containing 86 amino 
acid residues), insulin (a 51-amino acid polypeptide) and c-peptide, a precise marker of endogenous 
insulin secretion due to its resistance to degradation by liver during the first pass metabolism (Hebrok and 
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Russ, 2017). Insulin and c-peptide are released from the pancreas in equimolar amounts into the portal 
circulation by glucose stimulated insulin secretion (Hebrok and Russ, 2017). 
 
 
Figure 1.3: Insulin synthesis process.   
Source: Adapted from Namrata Chhabra, Diabetes mellitus, Insulin chemistry and Function.  
 
Insulin secretion by the pancreatic beta cells of the pancreas is regulated primarily and largely by the 
plasma glucose concentrations, amino acids (e.g. leucine), fatty acids and drugs (e.g. sulphonylureas, 
repaglinide and nateglinide)  (Gunton and Girgis, 2012). Glucose enters β-pancreatic cells via facilitated 
transport through membrane associated  specialized glucose transporters (GLUT-2) and is phosphorylated 
by glucokinase in the cytosol to glucose-6 phosphate, and subsequently metabolized through the 
glycolytic pathway to generate Adenosine Tri-Phosphate (ATP) (Hatting et al., 2018). The increase in 
cellular ATP levels causes a closure of the ATP-sensitive K
+
 channels present on the beta- cell 
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membranes; this leads to membrane depolarization, calcium entry through voltage-gated calcium channels 
and release of insulin into portal circulation by exocytosis (Gunton and Girgis, 2012). 
 
Figure 1.4: Insulin release from pancreatic beta cells in response to increased glucose.  
Source: Adapted from Gunton and Girgis, 2012. Pancreatic beta-cell failure in the pathogenesis of type 2 
diabetes.  
1.4.5 Insulin action on peripheral tissues 
The liver, muscle and adipose tissues are insulin sensitive tissues, on which insulin exerts its effects 
through interactions with heterodimeric insulin receptors (IR) (Petersen and Shulman, 2018). IR is a 
tyrosine kinase transmembrane receptor activated by a small group of endogenous ligands including 
insulin, Insulin like Growth Factor I and II (IGF-I and IGF-II).  It consist of two α  receptors that serve as 
the ligand binding domain located in the cell membranes and two intracellular β receptor domains that 
have intrinsic tyrosine kinase activity essential for insulin receptor function . The binding of insulin to the 
α-subunit causes an activation of the β-subunit tyrosine kinase, leading to the autophosphorylation of the 
receptor, phosphorylation (activation) insulin receptor substrate (IRS) proteins, (IRS1–IRS4) and 
subsequent activation of multiple downstream signaling cascades, including PI-3K and the MAP kinase 
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pathways, which mediate the metabolic and mitogenic activities of insulin in tissues (Petersen and 
Shulman, 2018, Haeusler et al., 2018, Boucher et al., 2014). 
 
 
Figure 1.5: Mechanism of action of Insulin.  
Source: Adapted from Namrata Chhabra, Diabetes mellitus, Insulin chemistry and Function. 
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In non-diabetics, insulin promotes hepatic glucose uptake and increased uptake of glucose by insulin-
sensitive peripheral tissues including skeletal muscle and adipose tissue where glucose is converted to 
glycogen and triglycerides, respectively (Kotronen et al., 2017).  Furthermore, insulin enhances positive 
nitrogen balance in tissue by facilitating uptake of amino acids in response to protein feeding, prevents 
protein breakdown and to a lesser extent stimulates protein synthesis (Abdulla et al., 2016).  In the 
adipose tissues insulin accelerates triglyceride incorporation by stimulating lipoprotein lipase and 
simultaneously inhibiting hormone sensitive lipases which catalyzes the hydrolysis of stored triglycerides 
(Lambadiari et al., 2015).  Insulin inhibits lipolysis, promotes triglyceride synthesis in adipose tissues, 
and suppresses endogenous production of glucose (gluconeogenesis and glycogenolysis) consequently 
promoting anabolism (Lambadiari et al., 2015). Deficiency of insulin in T1DM reduces glycogen 
synthesis allowing stimulatory effects of glucagon on glycogenolysis to predominate (Perry et al., 2014). 
Counter-regulatory hormones (glucagon, growth hormone, cortisol and catecholamines) are produced in 
response to marked insulin deficiency, stress and illnesses; they oppose the anabolic actions of insulin 
through endogenous glucose production  (Ghorani et al., 2016).  Glucagon is produced in the α-cell of the 
pancreas in response to hypoglycaemia, amino acids or autonomic nervous system activation and exerts 
its effects via cyclic adenosine monophosphate-dependent (cAMP) increases in glycogenolysis, 
gluconeogenesis and ketogenesis (Briant et al., 2016, Ravnskjaer et al., 2015).  In T1DM, hyperglycaemia 
does not inhibit the secretion of glucagon from the α-cells as expected in normal individuals; this due to 
loss of insulin‘s restraining effect on α-cells which leads to a relative increase in portal glucagon levels 
(Perry et al., 2014). Furthermore, growth hormone levels in T1DM are inappropriately elevated secondary 
to increased circulating levels of insulin-like growth factor (IGF) arising from insulin deficiency, growth 
hormone promotes lipolysis and inhibition of glucose utilization (Møller and Jørgensen, 2009).  Low 
portal insulin in T1DM allows for growth hormone-induced stimulation of gluconeogenesis contributing 
to an already detrimental hyperglycaemic state (Møller and Jørgensen, 2009). 
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Figure 1.6: Insulin effects in the skeletal muscle, liver and adipose tissue.  
Source: Adapted from Qaid, M.M. and Abdelrahman, M.M., 2016. 
 
1.4.6 Etiology and Pathophysiology of Type 1 Diabetes Mellitus 
TIDM is caused by profound pancreatic β-cell failure which results from an interplay of genetic, 
environmental and autoimmune factors that selectively destroy insulin producing β-cells (Figure 1.7) 
(Rahaman et al., 2015).  Human leukocytes antigen (HLA) genes found on the short arm of chromosome 
6 have been identified to be strongly associated with T1DM.  Identical HLA genes in siblings increase the 
risk of developing TIDM, which appears to be less if they do not share HLA genes (Noble, 2015). 
Specific HLA haplotypes associated with TIDM include HLA DR3 or DR4 class II molecules which are 
expressed in 90-95% of TIDM patients (Noble, 2015).  Other identified HLA haplotypes associated with 
TIDM disease susceptibility are the HLA DQ genes (DQ8 and DQ2) which are strongly linked with 
TIDM susceptibility in the Caucasian populations.  Because of heterogeneity, genetic associations do not 
fully account for susceptibility to diabetes (Noble, 2015). 
27 
 
Environmental triggers such as toxins, viruses and diet are important contributors to the development of 
TIDM.  Viral epidemics of mumps, congenital rubella and Coxsackie virus infections are associated with 
increased frequency of occurrence of TIDM and are as a result of autoimmune responses leading to the 
destruction of pancreatic beta cells (Ting et al., 2013, Beyan and Leslie, 2007). The mechanism of this 
beta cell destruction involves self-reactive cytotoxic CD8
+
 T-lymphocytes (CTL) and CD4
+
 lymphocytes, 
which recognize self-antigens expressed on β-cells leading to their apoptosis through different 
mechanisms including Fas receptor activation, perforin and granzyme-induced cell death (Espinosa-
Carrasco et al., 2018, Trivedi et al., 2016). 
Apart from CTLs, CD4
+
 T- cells contribute to the destruction of beta cells in TIDM, through the 
recruitment of CD8
+
 T-cells to infiltrate pancreatic islets tissue through the secretion of proinflammatory 
cytokines (TNF-α and IFN-γ).  These cytokines also activate and recruit dendritic cells, natural killer cells 
and macrophages that propagate the destruction of β-cells of the pancreas (Espinosa-Carrasco et al., 2018, 
Trivedi et al., 2016). 
 
Figure 1.7: Pathophysiology of Type 1 diabetes mellitus integrating the genetic, environmental and 
autoimmune components. (Source: Van Belle TL, Coppieters KT and Von Herrath MG 2011, Type 1 
Diabetes mellitus: Etiology, Immunity and Therapeutic strategies. 
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1.4.7 Etiology and Pathophysiology of Type 2 Diabetes Mellitus 
T2DM is caused by a complex interplay of environmental, genetic and lifestyle factors.  Lifestyle changes 
associated with the development of T2DM include excessive caloric intake (particularly energy dense 
foods), inadequate caloric expenditure (sedentary lifestyles) and obesity (weight greater than 120% of 
desirable weight) (Prasad and Groop, 2015, Murea et al., 2012).  Other predisposing factors associated 
with increased incidence of T2DM include low birth weight, age greater than 45 years, family history 
(first degree relatives), history of impaired glucose tolerance or impaired fasting insulin, dyslipidemia, 
history of gestational diabetes or previous birth of macrosomic babies, hypertension, pre-hypertension and 
polycystic ovarian syndrome (Murea et al., 2012, Temelkova-Kurktschiev and Stefanov, 2012). 
Development of T2DM involves combination of insulin resistance in the periphery and impaired insulin 
secretion resulting from pancreatic beta cell dysfunction  (Zaccardi et al., 2016).  Insulin resistance often 
occurs early in the evolution of T2DM before the onset of hyperglycemia and is associated with beta cell 
hyperfunction and hyperinsulinemia followed by beta cell failure at some point (Zaccardi et al., 2016, 
Keane et al., 2015). Obesity is an important contributing factor to insulin resistance in T2DM because it 
has a profound effect on tissue sensitivity to insulin and by extension glucose homeostasis. The 
mechanisms of insulin resistance in obese individuals involve interplay of elevated adipokine secretion, 
increased circulating free fatty acids and chronic inflammation of the adipose tissue (Keane et al., 2015). 
Insulin resistance results in decreased glucose transport into muscle cells, elevated hepatic glucose 
production, and increased breakdown of fat  (Rosen and Spiegelman, 2006).  Decreased insulin receptor 
affinity (arising from down-regulation, mutations and increased degradation) and impaired insulin 
receptor signaling are some of the mechanisms advocated to explain insulin resistance in the peripheral 
tissues (Khodabandehloo et al., 2016, Sharabi et al., 2015). Beta cell exhaustion in T2DM is due to a 
combination of compensatory failure and intrinsic beta cell defects (Kahn et al., 2014).  Furthermore, in 
T2DM, a loss of the reciprocal relationship between glucagon α-secreting cells and the insulin secreting 
beta cells characterized by glucagon excess suggests that T2DM is an islet paracrinopathy (Zaccardi et al., 
2016). 
1.5 Diabetes Mellitus and Highly active antiretroviral therapy  
The optimism generated by HAART has been forestalled by the recognition of an increasing array 
of adverse metabolic effects such as DM (Soepnel et al., 2017). Since   the   introduction of   HAART   in 
the mid-1990, abnormalities in glucose homeostasis have been reported with increasing frequency in 
persons with HIV (Brown et al., 2005). HIV-infected persons receiving HAART are at a 4-fold 
increased risk of developing diabetes compared with HIV-seronegative men (Brown et al., 2005).  In 
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May 1997, The FDA received 83 reports of the exacerbation of diabetes/ hyperglycemia in patients 
receiving HAART and by August 1997, issued a public health advisory warning regarding this adverse 
effect (Mastan et al., 2009). 
Studies have confirmed the association of hyperglycemia or DM with PI use (Chandwani and Shuter, 
2008). Recently, NRTIs and NNRTIs, were found to contribute to the disturbance of glucose 
metabolism (Ledgerber et al., 2007, Brown et al., 2005). Early cases of DM were linked to PI use, with 
cases of hyperglycemia appearing within 7 months of drug commencement (Chandwani and Shuter, 
2008).  Several  NRTIs  and  drug  combinations  were  related  to  the  development of DM, in 
particular, lamivudine-stavudine,  didanosine-stavudine,  and didanosine-tenofovir (Tesfaye et al., 2014, 
Dimala et al., 2016a). Didanosine and stavudine which are the most currently used NRTIs have been linked 
to cause mitochondrial toxicity by inhibiting mitochondrial DNA polymerase-γ. These two drugs are also 
strongly known for leading to DM (Brinkman and Kakuda, 2000, Kakuda, 2000). The mechanism 
behind diabetes risk due to HAART is complex and multifactorial (See figure 1.8). 
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Figure 1.8: Possible mechanisms behind diabetes risk due to antiretroviral therapy: Abbreviations: TNF, 
Tumor necrosis factor; IL-6, Interleukin- 6; GLUT-4, Glucose transporter type 4; FFA, Free fatty acid. 
Source: Kumar, K.E., and Mastan, S. 2011. Diabetes Mellitus Risk with HIV infection treated with 
Antiretroviral therapy – An Overview. 
1.6 Diabetic complications 
Complications arising from DM are both microvascular (diabetic nephropathy, neuropathy, retinopathy, 
etc.) and macrovascular (coronary arterial disease, peripheral arterial disease, stroke, etc.) in nature. These 
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complications of DM are well-known and are associated with long-term damage and failure of various 
organ systems (Chawla et al., 2016). 
The line of demarcation between the pathogenic mechanisms of microvascular and macrovascular 
complications of diabetes is blurred and these are reported to be the most prevalent contributors to 
morbidity and mortality on the global front (Chawla et al., 2016). It has been reported that diabetes 
induces pathognomonic changes in the microvasculature of the retina and the glomerular basement 
membrane by increasing their thickness, leading to diabetic microangiopathy. (Chawla et al., 2016). This 
glomerular basement membrane thickening will eventually lead to podocyte effacement, abnormal 
glomerular filtration rate as a result of damaged surface area and also narrowing of the vessels, inducing 
multiple clinical problems such as hypertension and tissue hypoxia (Chawla et al., 2016). Advanced 
glycation end products (AGE) and oxidative stress are accompanied with these changes and can lead to 
macrovascular complications (Asmat et al., 2016, Nowotny et al., 2015). 
Oxidative stress, caused by the overproduction of reactive oxygen species (ROS) plays an important role 
in the activation of other pathogenic pathways involved in diabetic complications, including elevated 
polyol pathway activity, nonenzymatic glycation, and protein kinase C (PKC) levels which in turn lead to 
the development of micro and macrovascular complications (Asmat et al., 2016, Nowotny et al., 2015). 
Microvascular complications include retinopathy, nephropathy and neuropathy while macrovascular 
complications include cardiovascular diseases, cerebrovascular diseases and peripheral vascular diseases. 
1.6.1 Diabetic nephropathy   
Diabetic nephropathy (DN) is one of the causes of renal failure globally. Patients with early renal damage 
manifest with microalbuminuria which progresses into proteinuria (Kanwar et al., 2008). In renal tissue, 
advanced glycation end products can induce activities of transforming growth factor and raise expressions 
of various extracellular matrix mRNAs. These mediate hypertrophy of the glomeruli, thickening of basal 
membrane, and expansion of the mesangial extracellular matrix (Kanwar et al., 2008). The pathogenic 
mechanisms underlying DN involve generation of ROS, accumulation of advanced glycation end product 
(AGE), activation of intracellular signaling molecules such as protein kinase C (PKC) and over activity of 
the  the hexosamine pathway (See figure 1.9) (Kanwar et al., 2008).  These mechanisms are unified by the 
occurrence of overproduction of superoxide anions by the mitochondrial electron transport chain which is 
the principal pathophysiological mechanism of tissue damage in diabetes mellitus (Kanwar et al., 2008). 
Intracellular hyperglycaemia induces increased generation of ROS from the mitochondrial and ultimately 
predisposes to oxidative stress, a common denominator of diabetic nephropathy disease development and 
progression (Kanwar et al., 2008). 
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Figure 1.9: Schematic illustration for the pathogenesis of diabetic nephropathy. Source: Sandireddy et 
al., 2014. Neuroinflammation and oxidative stress in diabetic neuropathy: futuristic strategies based on 
these targets. 
1.7 Oxidative stress 
Oxidative stress is an imbalance between ROS production and ROS detoxification; oxidative damage to 
tissues occurs when the ROS production exceeds the ROS degrading enzymes detoxifying capacity or if 
there is a depletion of antioxidants in the presence of excess ROS (Sies, 2015, Schieber and Chandel, 
2014). DM is strongly associated with increased oxidative stress which stems from increased ROS 
generation in tissues and a depletion of natural enzyme antioxidants expression and activity (Asmat et al., 
2016). The development and progression of diabetic nephropathy are promoted by increased and 
uncontrolled generation of ROS and the reduction in scavenger antioxidant enzyme activity (Kanwar et 
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al., 2008).  Increased ROS generation and depletion of natural antioxidant enzymes in T2DM have been 
previously reported (Panahi et al., 2017). 
1.8 Reactive Oxygen Species  
Reactive oxygen species (ROS) are highly unstable oxygen-based chemical species, these atoms are 
capable of independent existence and they contain one or more unpaired electrons in their outer orbit 
which makes them highly reactive entities.  ROS include both free radicals [e.g. superoxide anions (O2
-
*), 
Hydroxyl anions (OH*), peroxyl (RO2*) and alkoxyl radicals (RO*)] and chemicals capable of generating 
free radicals such as hydrogen peroxide (H2O2) (Knaus, 2018). ROS are generated in normal 
physiological processes (cellular respiration) in the mitochondria or pathological processes such as 
diabetes (Nishikawa et al., 2015). Although, mitochondria is a major source of ROS in diabetes, non-
mitochondrial sources include Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme, 
xanthine oxido-reductase system and nitric oxide synthase pathway (Inoguchi et al., 2003). 
Increased ROS production can oxidatively damage lipids, proteins and nucleic acids through interactions 
with redox-sensitive cysteine residues on proteins leading to the formation of sulfonic acids (-SOH) that 
form disulphide bonds (-S-S-) with neighbouring cysteine groups  (Zorov et al., 2014).  Furthermore, 
ROS interactions with polyunsaturated fatty acids in lipid membranes generate a series of reactive hydro-
peroxides that further damage membranes leading to structural and functional deficits (Sies, 2013). ROS 
through the formation of DNA adducts damages the DNA, causes loss of DNA repair mechanism and 
induce gene activation of oxidative-stress responsive maladaptive pathways thereby promoting apoptosis 
in glomerular cells which leads to characteristic morphological and functional abnormalities associated 
with the diabetic nephropathy (Reidy et al., 2014, Terryn and Devuyst, 2011). 
1.8.1 Lipid Peroxidation 
Both TIDM and T2DM are characterized by oxidative damage to macromolecules such as lipids, proteins 
and nucleic acids (Rani et al., 2016). Oxidative damage to lipids occurs by lipid peroxidation, a known 
biomarker of oxidative stress in tissues; it involves oxidative modification of lipids in tissues leading to 
deterioration of unsaturated lipids in plasma and organelle membranes (Frankel, 2014, Ayala et al., 2014).  
Peroxidation of membrane lipids involves the conversion of non-radical lipids into radicals, through a 
series of chain reactions  (Repetto et al., 2012, Frankel, 2014).  Lipids maintain cellular integrity through 
the abundant polyunsaturated fatty acids (PUFA) in biological membranes and are targets of peroxidation 
by free radicals ( Ayala et al., 2014, Holman, 2009).  Peroxidation of PUFA affects the structure and 
function of biological membranes through the alteration of their biophysical properties leading to loss of 
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fluidity and cellular integrity resulting in leakage of intracellular enzymes, failure of membrane pumps 
and impairment of cellular transport processes and activation of apoptosis ( Ayala et al., 2014, Holman, 
2009). 
1.8.2 NADPH Oxidase  
NADPH oxidase is a major source of intrarenal oxidative stress and is upregulated by metabolic factors 
leading to overproduction of ROS in podocytes, endothelial cells, and mesangial cells in glomeruli, which 
is closely associated with the initiation and progression of glomerular diseases (Wan et al.,2016). 
Membrane bound NADPH oxidases are important cellular sources of ROS which are pertinent to the 
pathophysiological processes in diabetic nephropathy (Wan et al., 2016, Fu et al., 2010). Diabetic 
nephropathy is often characterized by increased expression of NADPH oxidase isoforms, attenuated 
antioxidant defenses coupled with increased ROS generation (Jha et al., 2017, Zhang et al., 2017). 
Inhibition of NADPH oxidase-derived ROS generation mitigates diabetes- induced glomerular injury via 
reducing podocyte loss, proteinuria, glomerular hypertrophy, and mesangial matrix expansion (Wan et 
al.,2016, Asaba et al., 2007, Tojo et al., 2005). 
Podocytes depletion due to apoptosis occurs early in DN and is characterized by effacement of the 
podocytes foot process and slit disruption as reported by Wan et al., 2016; Some researchers have 
highlighted the role of podocytes in DN pathogenesis and have revealed the upregulation of NADPH 
oxidase subunits expression in type 1 diabetic OVE26 mice and type 2 diabetic db/db mice (Wan et al., 
2016 , Eid et al., 2009, Zhou et al., 2009) In vitro studies shows that high glucose induced the 
upregulation of NADPH oxidase expression, enhancement of NADPH oxidase activity, and apoptosis 
induction in podocytes at later time points (Wan et al., 2016, Susztak et al., 2006). (Eid et al., 2010) found 
that the increase of Nox4 expression was attributed to the inactivation of AMP-activated protein kinase 
(AMPK), and Nox4 promoted podocyte apoptosis via p53- dependent apoptotic pathway in high glucose 
condition.  
In the diabetic nephropathy, NADPH oxidase is up-regulated and is a major source of ROS generation 
which contributes to complications of diabetes in tissues (Zhang et al., 2017).  NADPH oxidase is 
activated in response to a variety of growth factors and protein regulators of cellular processes including 
angiotensin II, endothelin-1 (ET-1) and protein kinase C (Gill and Wilcox, 2006).  NADPH oxidase 
activation in diabetes is dependent on hyperglycemia where excessive glucose is channeled into 
glycolytic pathways leading to the accumulation of diacylglycerol (DAG), a potent activator of protein 
kinase C (Zhu et al., 2015).  PKC-dependent NADPH oxidase activation has been demonstrated to 
increase oxidative stress in the kidney (Yang et al., 2012, Zhu et al., 2015).  Angiotensin II is also an 
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important growth factor that has been strongly linked with increased development of fibrosis, which is a 
prominent feature of diabetic nephropathy and its elevation due to hyperglycemia directly activates 
NADPH oxidase activity in diabetic tissues. This causes marked increase in ROS levels in kidney tissues 
contributing significantly to the development of fibrosis and hypertrophy  (Garrido and Griendling, 2009).   
1.9 Natural Enzyme Antioxidants 
Maintenance of health is highly dependent on the fine balance between ROS production and its 
degradation by cellular antioxidants. Aerobic organisms possess sophisticated antioxidant defense 
mechanisms to detoxify ROS generated under physiological processes, such as protein-based enzyme 
antioxidants and non-enzymatic antioxidants which eliminate free radical intermediates in cells (Jiang and 
Xiong, 2016).  Enzymatic antioxidants in kidney tissues include superoxide dismutase (SOD), glutathione 
peroxidase (GPx) and catalase (CAT). Hyperglycaemia is suggested to directly impair endogenous 
antioxidant enzymes through a mechanism that is still debatable (Bajaj and Khan, 2012). 
1.9.1 Superoxide Dismutase 
Superoxide dismutase (SOD) is an important metalloenzymes that catalyse the conversion of superoxides 
to hydrogen peroxide thus limiting intracellular levels of superoxide and attendant oxidative damage.  
Three isoforms of SOD are recognised based on their metal content and cellular location, Cu-Zn SOD 
(cytosol and intramembranous space of mitochondria), Mn-SOD (mitochondrial matrix) and Fe-SOD 
(extracellular matrix) (Azarabadi et al., 2017, Kim et al., 2015).  Down-regulation or deletion of Mn-SOD 
genes in mice is associated with gross nephropathy and endothelial thickening, suggesting a protective role 
of MnSOD against mitochondrial superoxide-induced damage (Vara and Pula, 2014).  Cu-Zn SOD 
protects against oxidative damages in the cytoplasm, nucleus and mitochondria. SODs in general, are 
therefore critical to the maintenance of oxidative balance in tissue since they detoxify superoxides from 
multiple sources such as NADPH oxidases, mitochondria respiratory chain and eNOS uncoupling (Vara 
and Pula, 2014). In diabetes, hyperglycemia impairs circulating and tissue (heart, renal, hepatic and brain) 
SOD expressions and activity, both in humans and experimental animals (Giacco and Brownlee, 2010). 
1.9.2 Catalase 
Catalase is another dismutase enzyme. It contains a heme moiety at the active site and converts two 
hydrogen peroxide molecules to oxygen and water. This reaction requires the presence of a small amount 
of hydrogen peroxide to bind at the active site in order to generate catalase compound, which reacts with 
a second molecule of hydrogen peroxide (Keilin and Hartree, 1945). 
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During the enzymatic reaction leading to H2O2 destruction, catalase is first oxidized to a hypervalent iron 
intermediate, known as compound I (Cpd I), which is then reduced back to the resting state by a second 
H2O2 molecule. The first reaction is characterized by the oxidation of the heme protein by a single 
H2O2molecule leading to the formation of Cpd I, an oxoferryl porphyrin cation radical (Jones and 
Dunford, 2005). Once Cpd I is formed, it reacts rapidly with a second molecule of H2O2 to generate H2O 
and O2 in a two-electron redox process. This second reaction is particularly efficient in some catalases 
compared to other heme proteins such as myoglobin (Matsui et al., 1999).  
The first function assigned to catalase is the dismutation of H2O2 into oxygen and water without 
consummation of endogenous reducing equivalents, an important role in cell defense against oxidative 
damage by H2O2. Catalase may also have additional roles such as the detoxification or activation of toxic 
and anti-tumor compounds. For instance, catalase has been detected in mouse oocytes most likely to 
protect the genome from oxidative damage during meiotic maturation (Park et al., 2016). Under stress 
conditions, the antioxidant enzyme catalase plays a major role by detoxifying H2O2. As consequences, a 
change of its activity or expression will lead to pathological processes. 
1.10 Glutathione Peroxidase 
Efficient and rapid removal of oxygen-derived free radicals (by-products of aerobic metabolism) by 
suitable antioxidant systems such as glutathione peroxidase (GPx) is necessary to prevent the 
accumulation of ROS which can decompose into more harmful products that can cause oxidative damage 
to tissues (Lubos et al., 2011). Hydrogen peroxide and its decomposition product (hydroxyl ion (OH)) are 
generated in oxidative states and require an efficient removal system like GPx to prevent oxidative 
damage to tissue (Lubos et al., 2011). GPx reduces hydrogen peroxide (H2O2) and lipid peroxides into 
water and lipid alcohols, using glutathione as a hydrogen donor, they are selenium containing enzymes 
with 4 isoforms (GPx1-4) localized in different sub-cellular locations within cells (Brigelius-Flohé and 
Maiorino, 2013). 
GPx1 is expressed abundantly in the kidney tissue and is involved in most of the detoxification of H2O2 in 
the cytoplasm as well as organic peroxides such as cholesterol and long chain fatty acid peroxides 
(Crawford et al., 2011).  The protein expression of GPx1 has previously been reported to be reduced in 
diabetic rats in vivo leading to accelerated diabetes-induced atherosclerosis through the up-regulation of 
pro-inflammatory and pro-fibrotic mechanisms  (Shanmugam et al., 2011). GPx-2 is a tetrameric protein 
also localized in the cytosol and has 65% amino acid sequence identity with GPx-1 which explains their 
similar substrate specificities. GPx-3 is a glycoprotein found in plasma with extracellular functions unlike 
GPx-4, a monomeric protein found in different tissues with capacity to reduce phospholipid and hydrogen 
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peroxides.  GPx protein levels are generally reduced in the kidney, brain and heart of diabetic patients and 
animals (Crawford et al., 2011). 
1.11 Reduced Glutathione (GSH)  
Glutathione is an important tripeptidethiol (γ-glutamylcysteinyl glycine) antioxidant composted of three 
amino acids, cysteine, glycine, and glutamate. It is an important tripeptidethiol antioxidant widely 
distributed in biological fluids and tissues of plants, animals, fungi, some bacteria and archaea (Flora et 
al., 2013). It is associated with many physiological functions, such as the transportation of amino acids, 
the synthesis of proteins and DNA, the stabilization of cell membranes and the detoxification of 
xenobiotics (Flora e al., 2013). Glutathione plays an important role in fighting against toxic effects 
brought by reactive oxygen species like free radicals, lipid peroxides, peroxides and heavy metals. The 
reduced glutathione/oxidized glutathione ratio (GSH/GSSG) is widely used in clinics for the evaluation of 
oxidative stress status in biological systems (Gil et al., 2011).  
GSH is found in high concentrations in cellular systems and plays a major role in detoxification of 
various electrophilic compounds (Flora et al., 2013). GSH and GSSG work together with other redox-
active compounds such as NADPH to maintain and regulate cellular redox status. GSH is quantitatively 
described as the redox potential. Because of its significant role, acting as an antioxidant in the organism, it 
is of great interest among pharmacologists to take GSH system as a possible target for medical 
interventions (Flora et al., 2013). 
 
Deficiency of glutathione puts the cell at risk for oxidative damage. Besides its antioxidant defense and 
free radical scavenging, glutathione regenerates important antioxidants such as vitamins C and E. 
Glutathione maintains the redox state of critical protein sulfhydryl groups that are necessary for DNA 
repair (Gil et al., 2011). Besides neutralization of free radicals, glutathione also is suggested to chelate 
transition metals, thereby reducing their toxic ability
 
(Flora et al., 2013). Glutathione is known to be both 
a carrier of mercury as well as an antioxidant with specific roles in protecting the body from mercury 
toxicity. Glutathione targets and binds methyl mercury, preventing it from binding to other cellular 
proteins, which results in organ damage. Glutathione also prevents mercury from entering the intracellular 
environment and becoming an intracellular toxin. It has been suggested that IV glutathione combined 
with EDTA chelation significantly increases cadmium excretion (Flora et al., 2013, Gil et al., 2011). It 
was also found that renal protection was augmented. However, this was conducted in a single patient, 
albeit in a controlled fashion. This suggests that glutathione could provide additional chelation in the 
proper setting, but needs verification in clinical trials (Gil et al., 2011). 
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1.12 Role of Reactive Oxygen Specie in the pathogenesis of Diabetic nephropathy 
It has been reported that ROS play crucial role in the development of diabetic complications and oxidative 
stress is increased in diabetes with excessive production of ROS which is a direct consequence of 
hyperglycemia (Ha et al., 2008, Lee et al., 2007). Under hyperglycemic condition, various types of 
vascular cells including renal cells produces ROS (Ha et al., 2008). ROS mediate hyperglycemia- induced 
activation of signal transduction cascades and transcription factors leading to transcriptional activation of 
profibrotic genes in the kidney (Ha et al., 2008). The mechanisms underlying ROS induction signal 
transduction cascades and transcription factors involves oxidative damage to DNA and the mitochondria 
apparatus, leading to the activation of pro-apoptotic signalling events that culminate in cell death (Reidy 
et al., 2014). Commonly activated pro-apoptotic signalling molecules and factors include mitogen 
activated protein kinases (MAPKs) such as c-Jun N-terminal kinase (JNK), extracellular signal-regulated 
kinase (ERK) 1/2 and p38 MAPK (Yang et al., 2014). MAPK are important signal transduction enzymes 
that are unique to eukaryotes and are involved in many cellular processes, including development, 
differentiation, proliferation and apoptosis (Manna and Stocco, 2011). 
1.13 Streptozotocin model of Diabetes Mellitus 
Streptozotocin (STZ)-induced diabetic model is an extensively used animal model in studies of human 
diabetes mellitus. STZ is a nitrosourea antibiotic synthesized by streptomycetes achromogenes used in the 
induction of experimental diabetes. STZ selectively destroys pancreatic beta cells by alkylation of DNA 
through its nitrosourea moiety (Furman, 2015).  STZ, a glucosamine, is taken up preferentially by the 
pancreatic beta cells via membrane glucose transporter (GLUT-2) to induce oxidative damage leading to 
toxicity and cell death ultimately manifesting as insulin deficiency (Skovsø, 2014).  Intracellular 
metabolism of STZ leads to liberation of nitric oxide which mediates DNA damage and mitochondrial 
production leading to the release of superoxide ions (Skovsø, 2014).  Studies of STZ-induced DM models 
have identified abnormalities that include decreased kidney function and efficiency, decreased 
mitochondrial energetics, increased lipid storage, increased fatty acid oxidation, reduced glucose 
oxidation, impaired calcium handling and increased oxidative stress which are noted abnormalities in 
diabetic mellitus (Wu and Yan, 2015).  Furthermore, increased cellular ROS levels particularly enhanced 
superoxide generation, increased NADPH oxidase expression and decreased Glutathione disulfide 
/Gluthanione (GSSG/GSH) ratio (ratio of oxidized to reduced glutathione). All these have been reported 
by investigators of oxidative stress in STZ- induced diabetic nephropathy (Figgers et al., 2015).  The STZ 
diabetic model has been used by many investigators as a research tool in the partial or whole destruction 
of pancreatic beta cells for the discovery of antidiabetic drugs or diabetic complications. Administration 
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of low dose of STZ partially destroys the pancreas and thus implicates T2DM condition that resulting to 
hyperglycemia due to insulin resistance (Furman, 2015). 
Pancreatic beta cells are vulnerable to oxidative stress because of their particularly low quantity 
antioxidant enzymes. Damage to the pancreatic beta cells, would suppress glucose mediated insulin 
secretion. This effect could be mediated through increased oxidative stress (Figgers et al., 2015). 
Evidence from literature showed that adjunct therapy with antioxidants may ameliorate these deleterious 
consequences (El-Demerdash et al., 2018, Farzaei et al., 2015).  
1.14 Plants based adjuvants as putative antioxidants 
Plants based adjuvants have been shown to inhibit lipid peroxidation, chelate redox-active metals, and 
attenuate processes involving ROS in tissues (Offor et al., 2017a).  Although the health benefits of natural 
plants are mostly attributed to their antioxidant or free radical scavenging properties, it is becoming 
apparent that they exert more specific effects on a variety of cellular or molecular processes including cell 
signalling  (Ismail et al., 2018).   
An estimated 80% of Africans are said to rely on plant based adjuvants for the management of various 
disease conditions. For the majority of this group of individuals, consultation with traditional health 
practitioners (THP) is the first call for health services (Azu et al., 2016).  There has been increased interest 
in the role of plants as complementary alternative medicines (CAM) for the treatment of various acute and 
chronic diseases and previous studies support the use of plant-based adjuvants for disease management 
like diabetes, cancers, etc (Somanah et al., 2018, Kalantar-Zadeh and Fouque, 2017).  
It has also been estimated that up to one-third of patients with DM use some form of medicinal plants. 
Medicinal plants and its products continue to be an important therapeutic aid for alleviating the ailments 
of human kind and South Africa is a country with a long history of use of indigenous plants by herbalists 
and traditional healers for the treatment of various diseases such as HIV, diabetes and diabetic 
complications etc (Offor, 2015). 
Diabetic complications associated with HAART have attracted various studies designed to accommodate a 
holistic management approach including the use of medicinal herbal products. Thus, while the use of 
medicinal herbs, a principal component of CAM, predates the emergence of HAART, there has been a 
widespread increase in the consumption of herbal products as adjuvant in management of HIV (Offor, 
2015, Nyamukuru et al., 2017, Haile et al., 2017). Of the various classes of plants, interest has focused on 
medicinal plants with pharmacological properties and Momordica charantia plant is known to possess a 
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wide range of pharmacological properties such as antioxidant,  anti-diabetic, anti-inflammatory, 
antimicrobial, anticancer and anti-HIV properties (Gupta et al., 2011, Aljohi et al., 2018). 
1.15 Momordica charantia Linn. 
1.15.1 Plant description 
The plant Momordica charantia (M. charantia) is a flowering vine in the family of cucurbitaceous, 
known variously as bitter gourd, balsam pear, bitter melon, karela, bitter cucumber and African cucumber 
(Tirakannanavar and Munikrishnappa, 2011, Basch et al., 2003).  Although it has many culinary uses, 
especially in Asia countries, America and some east and Southern African countries particularly south 
Africa. It is also grown as an ornamental and is used extensively in folk medicine.  The fruits are cooked 
with other vegetables, stuffed, stir-fried or added in small quantities to beans and soups to provide a 
slightly bitter flavor. However, for most food preparation, fruits are blanched, parboiled or soaked in salt 
water before cooking to reduce the bitter taste. In addition to frying or cooking, the fruits can be 
dehydrated, pickled, or canned. Fruits, flowers and young shoots are also used as flavoring agents in 
various Asian dishes (Gupta et al., 2011). It is a climbing perennial plant that usually grows up to 5m and 
bears elongated fruits with a knobby surface. It is useful in a useful medicinal and vegetable plant for 
human health and one of the most promising plant for diabetes mellitus (Gupta et al., 2011). 
 
Figure 1:10: Photograph showing Plants of momordica charantia bearing fruits 
Source: Gupta et al., 2011 
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Figure 1:11:  Photograph showing leaves of momordica charantia 
Source: Gupta et al., 2011 
 
 
Figure 1:12: Photograph showing fruits of momordica charantia 
Source: Gupta et al., 2011 
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1.15.2 Medicinal Uses 
M. charantia has been used for centuries in the ancient traditional medicine of India, China, Africa and 
Latin America. M. charantia extracts possess antioxidant, antimicrobial, antiviral, antihepatotoxic and 
antiulcerogenic properties while also having the ability to lower blood glycaemia (Upadhyay et al., 2015, 
Raman and Lau 1996). These medicinal properties are attributed to an array of biologically active plant 
chemicals, including triterpenes, momordicine, charantin, polypeptide, vicine and steroids (Upadhyay et 
al., 2015). Ethnomedicine reports of M. charantia indicate that it is used in folkloric medicine for 
treatment of diabetes, various ulcers and infections (Upadhyay et al., 2015, Beloin et al., 2005). While the 
root decoctions have abortifacient properties, leaf and stem decoctions are used in treatment of dysentery, 
rheumatism and gout (Subratty et al., 2005). It is also known that juice of M. charantia which is gotten 
from fruit has traditionally been used for medicinal purposes globally (Upadhyay et al., 2015). Likewise, 
the extracted juice from leaf, fruit and even whole plant are routinely used for treatment of wounds, 
infections, parasites (e.g., worms), measles, hepatitis and fevers (Olivier et al., 2016, Behera et al., 2008).   
1.15.3 Phytochemical constituents 
Literatures have shown that M. charantia possesses so many phytochemical constituents. Few of this 
constituents arranged from A-Z are:  alanine, alkaloids, ascorbigen, b-sitosterol-d-glucoside, charantin, 
cucurbitins, cucurbitacins, cucurbitanes, diosgenin, elasterol, elaeostearic acids, glutamic acid, guanylate 
cyclase inhibitors, lauric acid, linoleic acid, linolenic acid, lutein, lycopene, momorcharasides, 
momorcharins, momordenol, momordicilin, nerolidol, oleanolic acid, oleic acid, oxalic acid, peptides, 
petroselinic acid, polypeptides, ribosome-inactivating proteins, rosmarinic acid, rubixanthin, serine, 
spinasterol, steroidal glycosides, stigmasta-diols, stigmasterol, trehalose, trypsin inhibitors, uracil, v-
insulin, vicine, zeatin ribosidezeinoxanthin amino acids-aspartic acid. Research has found that the leaves 
are nutritious sources of calcium, magnesium, potassium, phosphorus and iron; both the fruit and leaves 
are great sources of B-vitamins (Gupta et al., 2011, Joseph and Jini, 2013, Kumar et al., 2010). 
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Figure 1:13: Phytochemicals:  Momordicin  and  Charantin. 
Source: Kumar et al., 2010. A medicinal potency of Mormodica charantia. 
 
1.15.4 Selected bioactive compounds 
Based on the plethora of medical conditions that M. charantia can treat, scientists are more interested in 
studying its bioactive compounds and their actions on the body. However, as many studies have reported, 
there has been substantial emphasis on the anti-diabetic compounds and hypoglycemic properties (Tan et 
al., 2016, Daniel et al., 2014). A number of reported clinical studies have shown that M. charantia extract 
from the fruit, seeds, and leaves contain several bioactive compounds that have hypoglycemic activity in 
both diabetic animals and humans (Joseph and Jini, 2013).  Major bioactive compounds isolated from M. 
charantia and identified as hypoglycemic agents include charantin, polypeptide-p and vicine (Joseph and 
Jini, 2013, Chahar and Sharma, 2017). 
1.15.4.1 Charantin 
Charantin possesses antidiabetic properties and belongs to a typical cucurbitane- type triterpenoid in M. 
charantia  (Patel et al., 2010, Joseph and Jini, 2013). (Dhiman et al., 2012), demonstrated that charantin 
could be used to treat diabetes and can potentially replace treatment known antidiabetic drugs.  It is a 
mixture of two compounds namely, sitosterol glucoside and stigmasterol glucoside.  Studies have 
reported that charantin is more effective than the oral hypoglycemic agent tolbutamide (Cousens 2007). 
1.15.4.2 Polypeptide-p 
Polypeptide-p also known as p-insulin is an insulin-like hypoglycemic protein,  that has been reported by 
some researchers to cause hypoglycemia in gerbils, langurs and humans when injected subcutaneously 
 
Momordicin Charantin 
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(Joseph and Jini, 2013, Lo et al., 2013). Polypeptide-p works by imitating the action of human insulin and 
may be used as plant-based insulin replacement in type-1 diabetic patient (Joseph and Jini, 2013, Lo et al., 
2013). Recently (Wang et al., 2011), have cloned and expressed the 498 bp gene sequence coding for the 
M. charantia polypeptide-p gene and have also proved the hypoglycemic effect of the recombinant 
polypeptide in alloxan induced diabetic mice.  
1.15.4.3 Vicine 
Another major compound that has been isolated from the seeds of M. charantia is vicine. It is a 
pyrimidine nucleoside shown to induce hypoglycemia in non-diabetic fasting rats by intraperitoneal 
administration (Joseph and Jini, 2013, Zhang et al., 2004). 
1.15.5 Selected Pharmacological properties of M. charantia 
1.15.5.1 Antidiabetic activity 
The phytochemical constituents of M. charantia such as charantin, vicine, glycosides and polypeptide-p 
are hypoglycemic in action and improve blood sugar levels by increasing glucose uptake and glycogen 
synthesis in the liver (Gupta et al., 2011). These constituents is also known to restore a damaged insulin- 
secreting beta cells and enhance insulin release from the pancreatic beta cells (Ahamad et al., 2017). 
Kumar et al., 2010 and Shain et al., 2015, reports that a phytochemical constituent, (polypeptide) particularly 
from the seeds have been shown to decreased and normalize the blood sugar level in rats. M. charantia 
also contains another bioactive component known as lectin which mimics insulin action. This compound 
is known to reduce blood glucose levels by exerting its action on peripheral tissues. This common 
principle is similar to insulin‘s effects in brain in trying to suppress appetite. Lectin is an important 
compound for balancing blood glucose levels and develops after taking M. charantia (Jha et al., 2018, 
Jia et al., 2017). Another important phytochemical constituent is charantin. This can be extracted by 
alcohol and possesses rich hypoglycemic agents which are composed of mixed steroids. Charantin as a 
compound is useful in treating diabetes as it rapidly lowers blood glucose levels (Kumar et al., 2010, 
Dhiman et al., 2012).  
1.15.5.1.1 Possible mode of hypoglycemic action of M. charantia extracts  
These components of M. charantia extracts are believed to exert their blood glucose lowering effects via 
different physiological, pharmacological and biochemical modes (Singh et al., 2011, Garau et al., 2003, Platel 
and Srinivasan, 1995). Possibly, there mode of actions are: stimulation of peripheral and skeletal muscle 
glucose utilization, inhibition of intestinal glucose uptake, inhibition of adipocyte differentiation, 
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suppression of key gluconeogenic enzymes, stimulation of key enzyme of HMP pathway, and 
preservation of islet β cells and their functions (Singh et al., 2011, Joseph and Jini, 2013, Nerukar et al., 
2010).  
According to (Kim and Kim, 2011), M. charantia suppressed the activation of mitogen- activated protein 
kinases (MAPKs) and the activity of  nuclear factor kappa B (NF-kB). The findings shows that M. 
charantia protects pancreatic β-cells through down regulation of MAPKs and NF-KB in MIN6N8 cells 
(Kim and Kim, 2011). A similar study suggests that M. chanratia improves the serum and liver lipid 
profiles and serum glucose levels by modulating Peroxisome proliferator-activated receptor gamma 
(PPAR-γ) gene expression (Saad et al., 2017).  
1.15.5.2 Antioxidant activity 
Various parts of M. charantia have been used and are still in use to treat different diseases and to boost 
immunity in many parts of the world. Antioxidant activity of bitter melon has been reported by 
(Sathishsekar and Subramanian, 2005). There results showed that seeds of M. charantia normalized the 
impaired antioxidant status in streptozotocin induced- diabetic rats compared to the glibeclamide treated 
groups (Sathishsekar and Subramanian, 2005). 
1.15.5.3 Antiviral activity 
Alpha-and beta- momorcharin which are two proteins that are extracted from the seeds, fruits and leaves 
of M. charantia have been establish as a potent inhibitor of HIV in an in vitro study. HIV infected cells 
treated with these proteins showed a nearly complete loss of viral antigen (Lee-huang et al., 1990). This 
novelty led the inventors of the chemical protein along with anti-HIV protein (MAP-30) to file a U.S. 
patent, stating that it was ―useful for treating tumors and HIV infections‖. In treating HIV infection, the 
protein can be administered alone or in conjunction with conventional AIDS therapies (Gupta et al., 
2011). In another study, researchers also documented the in vitro antiviral activity against other viruses 
like Epstein-Barr and herpes viruses (Bourinbaiar and Leehuang, 1995, Lee-huang et al., 1995). 
1.16 Kidney: Organ of study 
The kidneys have important physiological functions including maintenance of water and electrolyte 
balance, secretion of hormones and excretion of waste products from the body. In addition, the kidneys 
also play a role in the excretion of drugs and xenobiotic, and hence may be exposed to high 
concentrations of drug metabolites making it liable to drug toxicity (Decloedt and Maartens, 2011).  It is 
therefore not a surprise that drug-induced kidney injury contributes up to 25% of all cases of acute renal 
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failure. Drug-induced kidney injury may cause cumulative dose-dependent toxicity or idiosyncratic dose-
independent toxicity at any time during therapy (Decloedt and Maartens, 2011). Kidney injury may occur 
in various areas of the kidney such as the glomerulus, the collecting ducts and the tubulointerstitium 
where exchange of solutes and reabsorption takes place (Decloedt and Maartens, 2011). 
During the process of metabolism, a lot of waste materials are produced in the tissues. Apart from these, 
the residue of undigested food, drugs, toxic substances and other pathogenic organisms like bacteria are 
also present in the body. All these substances must be removed to keep the body in a healthy condition. 
Although various organs in the body are involved in performing these functions, their excretory capacity 
is limited. The kidney has the maximum capacity of excretory function and so it plays the major role in 
homeostasis (Hall, 2015). 
1.17 Embryology of the mammalian kidney 
The mammalian kidney develops from intermediate mesoderm, proceeds through a series of three 
successive phases, each marked by the development of a more advanced pair of kidneys: the pronephros, 
mesonephros, and metanephros (Carlson, 2004). 
The pronephros develops at the beginning of the fourth week of intrauterine life (IUL) and is represented 
by 7 to 10 solid cell groups in the cervical region. These groups form vestigial excretory units, called 
nephrotomes that regresses before more caudal ones are formed. By the end of the fourth week of IUL, all 
indications of the pronephric system have disappeared (Sadler, 2018). 
The mesonephros and mesonephric ducts are derived from intermediate mesoderm from upper thoracic to 
upper lumbar segments. Early in the fourth week of IUL, during regression of the pronephric system, the 
first excretory tubules of the mesonephros appear. They lengthen rapidly, form an S-shaped loop and 
acquire a tuft of capillaries that will form a glomerulus at their medial extremity. Around the glomerulus 
the tubules form Bowman‘s capsule and together these structures constitute a renal corpuscle. Laterally 
the tubule enters the longitudinal collecting duct known as the mesonephric or Wolffian duct (Sadler, 
2018). 
The metanephros or permanent kidney appears in the fifth week of IUL. Its excretory units develop from 
metanephric mesoderm in the same manner as the mesonephric mesoderm. The collecting duct of the 
metanephros develops from the ureteric bud, an outgrowth of the mesonephric duct close to its entrance to 
the cloaca. The bud penetrates the metanephric blastema which is molded over its distal end as a cap. 
Subsequently the bud dilates forming the primitive renal pelvis and splits into cranial and caudal portions, 
the future major calyces. Each calyx forms two new buds while penetrating the metanephric tissue. These 
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buds continue to subdivide until 12 or more generations of tubules have formed. Meanwhile at the 
periphery more tubules form until the end of the fifth month of IUL. The tubules of the second order 
enlarge and absorb those of the third and fourth generations forming the minor calyces of renal pelvis. 
During further development, collecting tubules of the fifth and successive generations elongate and 
converge on the minor calyx forming the renal pyramid (Sadler, 2018). 
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Figure 1.14:  Picture showing embryology of the mammalian (human) kidney (Adopted from Medical 
embryology, Sadler 2018). 
A. Relationship of the intermediate mesoderm of the pronephric, mesonephric, and 
metanephric systems. In cervical and upper thoracic regions intermediate mesoderm is   
segmented; in lower thoracic, lumbar, and sacral regions it forms a solid, unsegmented 
mass of tissue, the nephrogenic cord. The longitudinal collecting duct is formed initially 
by the pronephros but later by the mesonephros.  
B. Excretory tubules of the pronephric and mesonephric systems in a 5-week old embryo.  
 
 
 
49 
 
1.18 Histology of the kidney 
Microscopic anatomy of the kidney shows that it is composed of interstitial cells and functional units 
called the nephron. Each nephron consists of tufts of anastomosing capillaries called the glomeruli, 
formed from the afferent arteriole and draining into the efferent arteriole and a tubular system called the 
renal tubule. Epithelial cells called podocytes (or visceral epithelium of Bowman's capsule) invest the 
glomerulus.  
The Bowman's capsule is the distended end of the tubular system and is invaginated by the glomerulus. 
The space between the glomerulus and Bowman‘s capsule is the urinary space. Extending from the 
capsule is the proximal tubule which is lined by cuboidal and columnar epithelial cells containing many 
mitochondria and a prominent brush border (Rouiller, C., 1969).  
The proximal convoluted tubule is the longest portion of the tubular system and is made up of convoluted 
proximal and distal straight (pars recta) segments. The pars recta descend into the medulla where it forms 
the U-shaped loop of Henle. The loop of Henle re-enters the cortex within which it forms the straight and 
convoluted segments of the distal tubule (Rouiller, C., 1969). 
The distal tubule runs close to the glomerular hilum and forms a specialized segment called the macula 
densa. The distal tubule is lined by cuboidal epithelium that lacks a brush border.  The distal tubule 
empties into collecting tubules which in turn drain into collecting ducts. The collecting duct converges as 
they approach the medulla to form the collecting ducts of Bellini which run vertically through the medulla 
to the papillae. The collecting tubules and ducts are lined by pale-staining, cuboidal epithelial cells 
(Rouiller, C., 1969). 
The interstitium is made up of the interstitial cells which consist of fibroblast-like cells, lipid-laden 
interstitial cells, macrophages, interstitial dendritic cells and perivascular cells. The fibroblast-like cells 
are mainly located in renal cortex and medulla, and have long cytoplasmic processes forming a reticular 
network between the tubules and capillaries (Rouiller, C., 1969). 
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Figure1.15:Photomicrograph of kidney tissue. Source: https://www.auanet.org/education-products-and-
resources/pathology-for-urologists/normal-histology-and-important-histo-anatomic-structures/kidney-
renal-corpuscle-(glomerulus). Assessed on 18
th
 May 2019. 
1.19 Glomerular filtration barrier 
The glomerular filtration barrier is made up of three layers of components which include: the fenestrated 
capillary endothelium, the intervening glomerular basement membrane and filtration slits between 
podocyte processes. The major component of the filter is formed by fusion of the basal laminae of a 
podocyte and a capillary endothelial cell (The McGraw-Hill Companies. Chapter 19. The Urinary 
System). 
(Figure 1.16): TEM showing cell bodies of two podocytes (PC) and the series of pedicels on the 
glomerular basement membrane separated by the filtration slits (arrows). On the other side of the 
membrane is the thin lining of a capillary (C) endothelial cell, with fenestrations. Together these openings 
allow filtration of liquid from plasma into the urinary space (US) of Bowman's capsule (The McGraw-
Hill Companies. Chapter 19. The Urinary System). 
(Figure 1.17): At higher magnification, both the fenestrations (arrowhead) in the capillary endothelium 
(E) and the filtration slits (arrows) separating the pedicels (P) are better seen on the two sides of the fused 
basal laminae (BL). The endothelial fenestrations in glomeruli lack diaphragms, but very thin slit 
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diaphragms cross the space between pedicels and play an important role in filtration (The McGraw-Hill 
Companies. Chapter 19. The Urinary System). 
 
 
Figure 1.16: Ultrastructural micrograph of the kidney. Source: (Mescher, 2013). Junqueira's basic 
histology: text and atlas, (The McGraw-Hill Companies.  Chapter 19. The Urinary System). 
 
 
Figure 1.17: Ultrastructural micrograph of the kidney. Source: (Mescher, 2013) Junqueira's basic 
histology: text and atlas, (The McGraw-Hill Companies.  Chapter 19. The Urinary System). 
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1.20 Gross anatomy of the mammalian kidney 
The kidneys are bilateral, bean-shaped excretory organs in vertebrates. In humans, the kidneys are located 
on the posterior abdominal wall in retro-peritoneal position with the right kidney slightly lower than the 
left due to the asymmetry within the abdominal cavity caused by the liver. The right kidney sits just 
below the diaphragm and posterior to the liver while the left kidney is below the diaphragm and posterior 
to the spleen. Each adult kidney weighs between 125 and 170g in males and between 115 and 155g in 
females. The left kidney is usually slightly larger than the right kidney (Fenton and Praetorius, 2016). 
Resting on top of each kidney is the adrenal gland. The upper  parts of the kidneys are partially protected 
by the eleventh and twelfth ribs, and each whole kidney and adrenal gland are surrounded by two layers 
of fat (the perirenal and pararenal fat) as well being covered by the renal fascia (Fenton and Praetorius, 
2016). 
Internally, the kidney is divided into the outer cortex and inner medulla. The medulla further divides into 
triangular shaped structures called the renal pyramids. The tip of each pyramid empties urine into a minor 
calyx; minor calyces empty into major calyces, and major calyces empty into the renal pelvis, which 
becomes the ureter as shown in figure 1.18 (Mescher, 2013). 
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Figure 1.18: Picture showing kidney: Source: Anthony L Mescher: Junqueira‘s Basic Histology 2013: 
Text and Atlas 15
th
 Edition. (The McGraw-Hill Companies. Chapter 19. The Urinary System). 
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1.21 Functions of the kidney 
The kidney performs the function of osmoregulation and excretion of subtances through the nephron by 
the following processes: 
1. Filtration of most small molecules from blood to form an ultra-filtrate of plasma. 
2. Selective reabsorption of most of the water and some other molecules from the ultra-filtrate, 
leaving behind excess and waste materials to be excreted. 
3. Secretion of some excretory products directly from blood into the urine. 
4. Maintenance of acid-base balance by selective secretion of H+ ions into the urine 
1.22 Kidney of other animals 
The kidney of fish, amphibians, reptiles, birds and mammals show increasing sophistication in 
conservation of water and minerals. The kidneys of fish and amphibians are typically narrow, elongated 
organs, occupying a significant portion of the trunk. The collecting ducts from each cluster of nephrons 
usually drain into an archinephric duct (Romer and Parsons, 1977). 
The kidneys of reptiles consist of a number of lobules arranged in a broadly linear pattern. Each lobule 
contains a single branch of the ureter in its center, into which the collecting ducts empty. Reptiles have 
relatively few nephrons compared with other amniotes of a similar size, possibly because of their lower 
metabolic rate (Romer and Parsons, 1977). 
Birds have relatively large, elongated kidneys, each of which is divided into three or more distinct lobes. 
The lobes consist of several small, irregularly arranged, lobules, each centered on a branch of the ureter. 
Birds have small glomeruli, but about twice as many nephrons as similarly sized mammals (Romer and 
Parsons, 1977). 
1.24 The rat kidney 
The rat kidneys are located ventrolateral to the vertebral column in the retro-peritoneum just like in 
humans and other mammals. Each rat kidney has a convex and a concave surface. The renal hilum lies in 
the concave surface and is the point where the renal artery enters the kidney and the renal vein and ureter 
exit. Internally, the parenchyma of the rat kidney is divided into two areas: the outer cortex and the inner 
medulla. The cortex extends into the medulla dividing it into triangular shapes known as renal pyramids. 
The renal pyramids contain the renal corpuscles and the convoluted tubular segments (Yoldas, A., and 
Dayan, M.O. 2014). 
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Each adult rat kidney contains roughly 30000-35000 nephrons. The nephron begins in the cortex with the 
renal corpuscle. The corpuscle consists of a capillary tuft (glomerulus) which is pushed into a blind 
expansion of the Bowman‘s capsule. The tubular part of the nephron consists of the proximal convoluted 
tubule, the loop of Henle and the distal convoluted tubule.  According to the location of the corpuscles in 
the cortex, the nephrons can be distinguished into three types: superficial, midcortical and juxtamedullary 
nephrons, and according to the length of the loop of Henle the nephrons of the rat kidney may be 
subdivided into two different types: nephrons with short loops and nephrons with long loops (Bachmann 
et al., 1986).  
1.23 Problem statement  
The metabolic disorder associated with HAART have become a public health problem contributing to 
more than 50% of kidney injuries, a fraction which may require immediate transplantation  (Fortuny et 
al., 2015). It is anticipated that as HIV/AIDS patients continue to depend on HAART for there survival, 
HAART-related metabolic disorders would correspondingly increase, this will imply a huge economic 
cost and care. The cost of HIV care in the United States is a critical issue considering that there are 
approximately 1.2 million PLWHA. A recent study estimated that the lifetime medical costs for an 
individual who becomes infected with HIV at age 35 was $326,500, with 60% of those expenses 
attributable to the costs of antiretroviral medication (Ritchwood et al., 2017, Schackman et al., 2015). 
This estimate was 3.3 times higher than the lifetime costs of medical care for high-risk individuals who 
remain uninfected and include the medical costs related to treating both HIV and non-HIV-related 
conditions. Between 2005 and 2015, HIV infections rose by 87% among young, African American. 
Additionally, in 2002, the costs associated with new HIV cases in the United States were estimated to be 
$6.7 billion in direct medical costs and $29.7 billion in indirect costs that result from productivity losses, 
which describes lost economic opportunities. The costs for lifetime treatment based upon the number of 
new diagnoses were estimated to be $16.6 billion in 2009 (Ritchwood et al., 2017, Chen et al., 2006). 
Longer lifespans and the over-representation of members from vulnerable groups living with the virus 
have important implications for healthcare systems, particularly as it relates to resource utilization and 
allocation, and cost expenditures (Ritchwood et al., 2017, Fleishman et al., 2005).  
 DM is a major degenerative disease, found in all parts of the world and it is becoming the third most 
lethal disease of mankind and increasing rapidly (Joseph and Jini, 2013, Ogbonnia et al., 2008). DN, 
which is one of the microvascular complications of diabetes characterized by overall decline in 
glomerular filtration rate and significant hypertrophy and hyperplasia of the kidney tissue, is a life 
threatening condition affecting large number individuals globally (Haneda et al., 2015). At present, DN 
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encompasses other diseases such as atheroembolic disease, ischemic nephropathy, and interstitial fibrosis 
that occur as a direct result of diabetes (Toth-Manikowski and Atta, 2015).  
While diabetes incidence and nephrotoxicity is increasing in the general population of PLWHAs, there is 
very little describing the relationship between diabetes and nephrotoxicity among HIV-infected 
population under HAART in South Africa.  
1.25 Justification for study  
The problem of drug toxicity continues to attract the attention of researchers both in experiments and 
clinical trials. Evidence shows that animal models of drug toxicity represent a similar pattern in humans. 
For example, one-third of all drugs associated with nephrotoxicity in animals resulted in liver enzyme 
elevation in humans (Amacher, 1998).  
Animal models of diabetes have provided understanding of pathogenesis and progression of diabetes 
mellitus in humans. Furthermore, animal models have allowed the evaluation of various therapeutic 
interventions which may be potentially used in man. Uses of animal models have made possible studies of 
disease characteristics in humans by providing genetic and immunological modifications that are not 
possible in humans (Van der Worp et al., 2010, Rees and Alcolado, 2005).  In this study, the rat serves as 
a suitable model for investigating the mammalian kidney based on its similar structure and physiologic 
functions, while being easy to handle and generally considered less expensive.  
The associated toxicities of HAART necessitate the need for safe and less costly adjuvants that can 
mitigate these effects. Plant-based extracts have the potential to fill this need due to its perceived 
effectiveness. An increasing reliance on the use of medicinal plants in industrialized societies has been 
traced to the extraction and development of several drugs and chemotherapeutics from these plants 
(Somanah et al., 2018).  
The Southern African ecosystem is replete with medicinal plants that continue to drive improvement in 
indigenous knowledge systems. Estimates of about 80% of the general population in sub-Saharan Africa 
rely on African traditional medicines to treat various diseases (Azu et al., 2016). M. charantia falls into 
this category. The plethora of activities attributed to M. charantia extracts particularly its radical 
scavenging antioxidant and antidiabetic actions makes it a potentially good therapeutic candidate that may 
mitigate the effects of HAART and hyperglycaemia-induced oxidative damage in the kidney associated 
with diabetes mellitus. However, the scientific validation of these claims remains to be verified. 
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1.26 Contribution to knowledge 
Results from this study would assist in the understanding of renal changes under diabetic condition with 
HAART hence provide elucidation of possible renal end-organ injuries. The result would shed further 
knowledge on the antioxidant, antidiabetic and anti-inflammatory properties of M. charantia in alleviating 
the associated toxicities of HAART. The publications that will emanate from this study will contribute to 
the existing body of knowledge on the potentials and usefulness of M. charantia as an adjuvant is 
mitigating nephrotoxicity and metabolic disorders. 
1.27 Research questions 
1. Does M. charantia ameliorate nephrotoxicity following HAART? 
2. Does M. charantia have anti-diabetic effects?  
3. Can M. charantia mitigate renal function impairment following HAART toxicity and diabetes in 
diabetic nephropathy? 
4. Can the known toxicities of HAART on the renal histo-morphology and renal ultrastructural 
changes be mitigated by the plant based adjuvant M. charantia? 
5. Can M. charantia improve mRNA expression profile of KIM-1, NGAL and TNF-α following 
HAART toxicity and diabetic nephropathy? 
1.28 Aim  
The overall aim of this study is: 
1.  To investigate the effects of M. charantia in the kidney following HAART in diabetic condition.  
1.29 Specific Objectives 
1. To determine the histomorphology of the kidneys using H&E, PAS and MT. 
2. To weekly measure blood glucose levels  
3. To evaluate urine samples every 3 weeks  
4. To measure renal function test 
5. To measure oxidative stress levels  
6. To determine the ultrastructural changes of the kidney in diabetic and non-diabetic animals.  
7. To determine the circulating mRNA expression profile of NGAL, KIM-1 and TNF-α in diabetic and 
non-diabetic animals. 
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1.30 Materials and Methods 
Ethical approval: 
The University of KwaZulu Natal Animal Research Ethics Committee gave full approval of the project 
with a reference number: AREC/033/016D. 
Antiretroviral drug 
Triplavar (Cipla-Medpro) containing Lamivudine 150 mg, Nevirapine 400 mg and Zidovudine 300 mg, 
was used for this study. The drug was obtained from Pharmed pharmaceuticals, Pty (Ltd) Durban, South 
Africa. 
Preparation of M. charantia fruit ethanolic extract  
Fifty kilogram of fresh mature unripe fruit of M. charantia was purchased from the local Durban markets 
between May-June 2016. Samples were authenticated at the herbarium unit of the Department of Life 
Sciences, University of KwaZulu-Natal, Durban, South Africa (voucher no. 4617). The fruits were 
cleaned, sliced into small pieces and the seeds separated out and discarded. The sliced green fruit was first 
weighed and then dried in shade for approximately 2 weeks. It was then weighed again to obtain the final 
dry weight before pulverizing into a fine power in a commercial grinder and stored at 5 
0
C until ready for 
extraction. The active ingredients were obtained by Soxhlet extraction using 100 % ethanol as the solvent. 
The solvent was evaporated in a rotary evaporator at 40°−50°C with a percentage yield of 85.25%. The 
wet residue was filtered through a whatman filter and the concentrated extract was stored at 4 
0
C ready for 
use. 
Animal management and Experimental design  
A total of seventy eight (78) adult male Sprague-Dawley rats weighing 178-232 grams were used for the 
study. The investigation was carried out at the Biomedical Research Unit Animal housing facility, 
University of KwaZulu-Natal, South Africa. The animals received humane care in accordance with the 
principle of laboratory animal care of the National Medical Research Council and the Guide and use of 
Laboratory animals of the National Academy of Sciences (National institute of health care 1985). All rats 
were housed in well ventilated plastic cages [3 rats per cage for the non-diabetic group (in 12 cages)] and 
[3 rats per cage for the diabetic group (in 14 cages)]. The dimensions of cages are (52 cm long × 36 cm 
wide and 24 cm high) and soft wood shavings served as beddings in the cages. Animals were maintained 
under standardized animal house conditions (temperature: 23–25 °C; light: approximately 12 h natural 
light per day) and were fed with standard rat pellets from (Meadow feeds a Division of Astral Operations 
Limited, Durban, South Africa) and given tap water ad libitum.  The initial body weight of the animals 
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were recorded before treatment and randomly distributed to non- diabetic group (A-F comprising 6 
animals per group) and diabetic group (G-L comprising 7 animals per group) as shown in the treatment 
schedules below.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.19: Flow charts showing groupings of animals and treatment schedules. 
 
TOTAL ANIMALS (78) SPRAGUE-
DAWLEY RATS 
NON-DIABETIC (36) 
DIABETIC (42) 
GROUP A 
-ve Control 
 
GROUP B 
Triplavar 
 
GROUP C 
M. Charantia 
200mg/kgbw 
GROUP D 
M. Charantia 
400mg/kgbw 
GROUP E 
M. Charantia 
(200mg/kgbw) 
+ Triplavar 
GROUP F 
M. Charantia 
(400mg/kgbw) + 
Triplavar 
 
GROUP G 
+ve Control
 
GROUP J 
M. Charantia 
(400mg/kgbw) 
 
GROUP K 
Triplavar +  
M. Charantia 
(200mg/kgbw) 
GROUP L 
Triplavar +  
M. Charantia 
(400mg/kgbw) 
 
GROUP H 
Triplavar 
 
GROUP I 
M. Charantia 
(200mg/kgbw) 
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Induction of diabetes mellitus 
All rats were placed on a 12 hours fast to obtain baseline fasting blood glucose levels (FBG). The 
experimental groups (B- G) were given intra-peritoneal streptozotocin (STZ) (Sigma-Aldrich Chemical 
Company, Missouri, St Louis, USA) at 45 mg/kg body weight dissolved in a citrate buffer (pH 4.5) (Etuk 
2010). Successful induction of diabetes was determined by observation of polyuria and polydipsia and 
confirmed by a 72 hours post STZ FBG level ≥11 mmol/L. 
Measurement of blood glucose  
Blood samples were obtained from the tail using sterile needle prick.  Glucose levels were measured once 
a week during the 10 weeks treatment using the one touch ultra-glucometer (Boehringer-Mannheim, 
Germany).  
Measurements of body weight and collection of urine samples 
All experimental animals were weighed weekly by a digital scale (Mettler-Toledo, 200). For collection of 
urine, the rats were placed in metabolic cages for 24 hour and provided with rat chow and water. The 
urine volume was measured and urine centrifuged to separate out debris. Urine samples were kept at -
80°C until further analysis. This procedure was done at weeks 3, 6 and 9 during the 10 week experimental 
period.   
Measurement of oxidative stress parameters and lipid peroxidation 
Blood was collected in plain tubes via cardiac puncture and allowed to clot. It was then centrifuged at 
3000 revolutions per minute (rpm) for 15 minutes and the serum decanted into eppendorf tubes and stored 
at –20
o
C for subsequent use. Serum was assayed for Lipid Peroxidation (LPO), Reduced Glutathione 
(GSH) level, Superoxide Dismutase (SOD) and Catalase activities (CAT). 
Serum lipid peroxidation levels  
This was measured using a complex formed from the reaction between malondialdehyde (MDA) and 
thiobarbituric acid (TBA) as described by  (Hodges et al., 1999) . Into an assay mixture containing 200 
µL of 8.1% sodium dodecyl sulfate (SDS), 750 µL of 20 % acetic acid (pH, 3.5), 2 mL of 0.25% TBA 
and 850 µL of distilled water, 200 µL of sample or MDA standard series (0, 7.5, 15, 22.5, and 30 µM) 
was added in a pyrex screw capped test tube. The mixture was heated at 95 
O
C for 60 min in a sand bath, 
cooled down to room temperature and absorbance was read at 532 nm in a spectrophotometer (UVmini-
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1240, Shimadzu Japan). Thiobarbituric acid reactive substances (TBARS) concentrations of samples were 
extrapolated from MDA standard curve. 
Serum reduced glutathione concentration (GSH)  
Reduced glutathione concentration was measured in serum according to methods modified from (Rahman 
et al., 2006). The sample was first precipitated with 10% Trichloroacetic acid (TCA) and then centrifuged 
at 2000 rpm for 10 min at 25 
O
C. The reaction mixture contained 400 µL of supernatant, 200 µL of 0.5 m 
5, 5'-dithiobis-(2-nitrobenzoic acid) (DTNB) and 1.2 mL of 0.2 M sodium phosphate buffer (pH, 7.8). 
Absorbance was measured at 415 nm after 15 min incubation at 25 
O
C and GSH concentrations of 
samples was extrapolated from standard curve of GSH. 
Anti-oxidant enzyme activities 
Superoxide dismutase  
Superoxide dismutase (SOD) activity was assayed according to the method of  (Weydert and Cullen 
2010)  A 15µL of 1.6 mm 6-hydoxydopamine (6-HD) was added to an assay mixture containing 170 µL 
of 0.1mm diethylenetriamine – penta acetic acid (DETAPAC) in 50 mm sodium phosphate buffer (pH, 
7.4) and 15µL of sample (serum) containing 0.1µg/µL of protein was used to start the reaction. The linear 
increase in absorbance was monitored at 490 nm for 5 min at 25 
O
C. One unit of enzyme activity was 
defined as the amount of enzyme required to oxidize 1µmol of 6-HD/min/µg protein. 
Catalase 
Catalase activity was measured using the method described by (Weydert and Cullen 2010). Into an assay 
mixture containing 340 µL of assay buffer (50 mm potassium phosphate buffer, pH 7.0) and 150 µL of 10 
mm H2O2, 10 µL of sample containing 0.1µg/µL protein was added to start the reaction. The linear 
increase in absorbance was monitored at 240 nm for 5min at 25 
O
C. One unit of enzyme activity was 
expressed as the amount of enzyme needed to decompose 1mmol of H2O2 /min/µg protein. 
Assessment of renal function 
Serum was used for the estimation of blood urea nitrogen (BUN) and serum creatinine (CR-S) using 
Beckman Coulter Synchron® system(s) BUN and CR-S assay kit. Beckman Coulter Synchron® system 
BUN assay kit and Beckman Coulter Synchron® system CR-S assay kit were obtained from Global Viral 
Laboratory, Durban, South Africa  
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RNA extraction and cDNA Synthesis  
Blood was collected in plain tubes via cardiac puncture and allowed to clot. It was then centrifuged at 
3000 revolutions per minute (rpm) for 15 minutes and the serum decanted into Eppendorf tubes and 
stored at –20
o
C pending RNA extraction.  RNA was isolated using the Zymo Research Quick-RNA™ 
Miniprep, CA-USA according manufacturer‘s protocol. The iScript cDNA synthesis kit (Bio-Rad, USA) 
was used to perform reverse transcription (RT). Manufactures protocol was followed in preparation of the 
reagents as well as volumes of reagents used.  
Real –Time Polymerase Chain Reaction    
The ROCHE light cycler SYBR Green I master mix was used to carry out PCR amplifications on 
ROCHE light cycler 96 machine. The Primer sequence used can be found in the table 1.7 below.  PCR 
was done using the following cycling conditions: Pre-incubation for 10 min at 95 °C, followed by 45 
cycles of 95 °C for 15 s, 60 °C for 30s and 72 °C for 30s. All samples were assayed in duplicate with a 
positive and negative control included in each run. The results were analysed using the 2
-ΔΔCq
 comparative 
method to compare Cq values of the treated groups to the control group. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) used to normalise the Cq values of the treated groups and control groups. To 
calculate the fold change, a value of 1 was assigned to the controls (Anier et al., 2010). 
Table 1.7: Gene primer sequence 
GENE FORWARD REVERSE 
TNF-α 5‘-GACCCTCACACTCAGATCATCCTTCT-3‘ 5‘-ACGCTGGCTCAGCCACTC-3‘ 
KIM-1  
5‘-AACGCA GCG ATT GTG CAT CC-3‘ 
 
5‘ -GTA CAC TCACCA TGG TAA CC-3‘ 
NGAL  
5‘-GAT GAA CTGAAG GAG CGA TTC-3‘ 
 
5‘-TCG GTG GGA ACAGAG AAA AC-3‘ 
GAPDH  
5‘-CCT GGA GAA ACCTGC CAA GTA T-3‘ 
 
5‘-AGC CCA GGA TGC CCT TTA GT-3‘ 
 
 
Histopathological Examination of the rat kidneys  
The rat kidneys were weighed and examined for any gross pathology. A phosphate buffer solution (PBS) 
was used to wash out blood before preparation for tissue fixation. Kidneys were fixed in 10% neutral 
buffered formalin for 24 hours. The samples were transferred to 70% ethanol solution. Ascending grades 
of alcohol (50%, 70%, 90%, 100%) were then used to dehydrate the samples and xylene was used as a 
clearing agent. The samples were immersed in molten paraffin wax at 58°C to 62°C. The prepared blocks 
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were cut into slices of 5 μm) using a microtome (Microtome HM 315, Walldorf, Germany) and stained 
with hematoxylin and eosin (H&E), periodic acid-Schiff (PAS) and Masson's trichrome (MT). 
Haematoxylin and Eosin (H&E) Staining 
Slides were placed in staining jar and deparaffinized by submerging into three series of absolute xylene 
for 4 minutes followed by 100%, 100%, 95%, 90%, and 70% of ethanol for 4 minutes of each percentage. 
Next, slides were washed in running tap water for 2 minutes. Then, slides were submerged into Harris 
Hematoxylin (Sigma-Aldrich, GERMANY) for 2 minutes and then washed in running tap water for 2 
minutes. The slides were then submerged into 1% acid alcohol for 3 dips to decolorize it and washed in 
running tap water for 2 minutes. After that, slides were submerged into Eosin for 2 minutes followed by 
washing in running tap water for 2 minutes. Stained slides were dried for 24 hours at 38°C. Before 
observation, slides were dipped into absolute xylene for 1 minute and finally mounted with cover slip 
using DPX mounting. 
Periodic acid Schiff (PAS) Staining 
PAS staining technique was used to detect the presence of polysaccharides (e.g., glycogen) and 
mucosubstances (e.g., glycoproteins, glycolipids, and mucins) in rat kidney tissues. Slides were placed in 
staining jar and deparaffinized by submerging into three series of absolute xylene for 4 minutes followed 
by 100%, 95%, 90%, and 70% of ethanol for 4 minutes of each percentage. Then slides were placed in 
distilled water for 3 minutes. Then, slides were submerged into Periodic Acid Solution for 5 minutes at 
room temperature (18–26°C). Next slides were rinsed well in several changes of distilled water. 
Thereafter slides were immersed in Schiff‘s reagent for 5-15 minutes at room temperature (18–26°C) 
until deep magenta. Next slides were washed in running tap water for 5 minutes and counterstained with 
haematoxylin solution for 1 minute. Next slides were rinsed in running tap water for 2 minutes. Slides 
were then dehydrated in graded series of alcohol of 70%, 80%, 95% and 100% for 1 minutes each 
percentage. Before observation, slides were dipped into absolute xylene for 1 minute and finally mounted 
with cover slip using DPX mounting. 
Masson’s Trichrome (MT) Staining 
The MT staining is a three-color staining protocol used in histology for kidney pathologies. It is suited for 
distinguishing cells from surrounding connective tissue staining red keratin and muscle fibers, blue or 
green collagen and bone, light red or pink cytoplasm, and dark brown to black cell nuclei. It also 
differentiates between collagen and smooth muscle in tumors, and the increase of collagen in diseases 
such as cirrhosis. It is a routine stain for kidney biopsies.  
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Method was modified from Dries, (2008). Slides were placed in staining jar and deparaffinised by 
submerging into three series of absolute xylene for 4 minutes each followed by 100%, 95%, 90%, 80% 
and 70% of ethanol for 4 minutes in each percentage. The slides then were submerged in warmed Bouin‘s 
solution at 60°C for 45 minutes. Next, the slides were washed in running tap water until yellow colour in 
samples disappeared. To differentiate nuclei, slides were then immersed in modified Weigert‘s 
haematoxylin for 8 minutes, after that washed in running water for 2 minutes. In order to stain cytoplasms 
and erythrocytes, slides were submerged in anionic dyes, acid fuschin (C.I. 42590, Merck, Germany) for 
5 minutes; then again slides were washed with running tap water for 2 minutes. Next, slides were treated 
with phosphomolybidic acid solution for another 10 minutes as a mordant and immediately slides were 
submerged into methyl blue (C.I. 42780, Merck, Germany) solution for 5 minutes in order to stain 
fibroblast and collagen. After that, slides were washed in running water for 2 minutes and lastly treated 
with 1% acetic acid solution for 1 minute. Slides were then dehydrated into a series of alcohol of 70%, 
80%, 95% and 100% for 1 minutes each percentage. Before observation, slides were dipped into absolute 
xylene for 1 minute and finally mounted with cover slip using DPX mounting. 
The sections were viewed and photographed using an Olympus light microscope (Olympus BX, Tokyo, 
Japan) with an attached camera (Olympus E-330, Olympus Optical Co. Ltd., Tokyo, 
Tissue preparation for electron microscopy 
Ultrastructure of the kidney was studied using the transmission electron microscope. To accomplish this 
aim, small samples (about 1 mm) cut from different areas of the kidney were fixed by immersion method 
in glutaraldehyde at 4°C overnight. Subsequently, the specimens were washed (4 x 15 min) in 0.1 M 
cacodylate buffer (pH 7.2). All samples were post-fixed in 1% osmium tetroxide for 2 hr. Later, they were 
washed again (3 x 20 min) in 0.1 M cacodylate buffer (pH 7.2). After dehydration in a graded series of 
ethanol (50%, 70%, 90%, 100%) and propylene oxide (Merck, Darmstadt, Germany) the specimens were 
gradually embedded in Spurr‘s Low Viscosity Resin (Polysciences, Eppelheim, Germany). Briefly, 
samples were firstly placed (2 x 15 min) in propylene oxide (Merck, Darmstadt, Germany) then in 
propylene-Spurr‘s resin mixture (2:1) for 1 hr, in propylene-Spurr‘s resin mixture (1:1) overnight and 
finally in pure Spurr‘s resin overnight.  
Thereafter, kidney specimens were embedded in silicon molds (Plannet, Wetzlar) containing Spurr‘s resin 
and polymerized at 70°C for 8 hr.  For general morphology, semi-thin sections (1μm) were cut using a 
Leica EM UC7 ultramicrotome (Leica, Germany) and stained with toluidine blue (Sigma-Aldrich 
Chemicals GmbH, Deisenhofen, Germany) for examination under light microscopy. Ultra-thin sections 
were then cut from selected blocks and mounted on copper grids (SSI, Science Services, Munich, 
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Germany) and routinely contrasted with uranyl-acetate and lead citrate prior to examination with a JEOL 
2100 HR TEM (JOEL, Japan).  
Statistical analysis 
Analyses were carried out using one-way analysis of variance, (ANOVA) followed by Dunnet‘s multiple 
comparison post-hoc tests using Graph pad prism ® statistical software version 5.02. Values were 
expressed as mean ± standard deviation (SD) and all results tested for significance at the 95% confidence 
level (p<0.05).   
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(Unpublished) 
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BRIDGING 
BETWEEN CHAPTER ONE AND CHAPTER TWO 
The introduction and literature review from chapter one reveal the remarkable contribution of highly 
active antiretroviral therapy (HAART) towards the management of HIV/AIDs epidemic globally. 
However the success achieved is not without side effects which in many settings are not monitored. 
Antiretroviral agents are responsible for a wide range of toxicities, from low-grade intolerance that may 
be self-limiting, to life-threatening side-effects.  As previously reported, plant-based adjuvants have been 
widely accepted and used for the management of various ailments with the potentials to fill the need for 
the management of comorbid disorders and toxicities emanating from the use of HAART. Thus, the next 
chapter evaluated the role of ethanolic extract of Mormodica charantia in the era of HAART on renal 
histoarchitecture and other biochemical parameters assessed in non-diabetic animals. 
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Highlights 
 Highly active antiretroviral therapy (HAART) associated nephrotoxicity is characterized by 
tubular necrosis with glomerular hypertrophy. 
 
 Derangements of the cytoarchitectural patterns of the kidney were seen as a result of treatment 
with HAART regimen (triplavar). 
 
 Co-administration of M. charantia and HAART mitigates the intensive histopathological changes 
of the rat kidney.  
 
 Nephrotoxicity is associated with increased oxidative stress which stems from increased reactive 
oxygen species (ROS) generation in tissues. 
 
 M. charantia possesses phytochemical properties which are powerful counter measures against 
oxidative stress tissue damage. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
95 
 
 Graphical abstract 
               
 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HAART 
ROS generation 
Oxidative 
stress 
Cytokines 
    TNF α and IL-6 
Mitochondrial 
dysfunction 
Antioxidant enzymes 
 SOD, CAT, GSH 
BUN, SCr, Albumin 
Sodium, Potassium 
 
 
Necrosis 
Momordica charantia 
Nephro
toxicity 
Glomerular injury 
 
Momordica charantia 
 
96 
 
 
97 
 
 
98 
 
 
99 
 
 
100 
 
 
101 
 
 
102 
 
 
103 
 
 
104 
 
BRIDGING 
BETWEEN CHAPTER TWO AND CHAPTER THREE 
The toxicity role of HAART on the kidney of non-diabetic Sprague-Dawley rats in chapter two of this 
study further supports previous researchers towards the untoward side effects of HAART.  However, 
another major concern linked to HAART that requires management is the undesired metabolic comorbid 
disorder (diabetic nephropathy) with its accompanied nephrotoxicity. The next chapter therefore 
evaluated the impact of Mormodica charantia on the kidney in diabetic condition following the treatment 
with HAART. 
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BRIDGING 
BETWEEN CHAPTER THREE AND CHAPTER FOUR 
In the previous chapters (Chapter two and three) treatment with HAART imposed varieties of ravages on 
the kidney histoarchitectural patterns ranging from tubular necrosis, glomerular capillary abnormalities 
and other biochemical results assessed. These were evident in the non-diabetic and diabetic induced 
animals. Mormodica chanratia was able to mitigate these adverse effects of HAART in both non-diabetic 
and diabetic state with restoration of the kidney histological structure and function owing to its plethora of 
phytochemical constituents. In other to understand the impact of Mormodica charantia at the subcellular 
level the study further investigated key components for determining renal integrity and function in the 
next chapter and also to explore other potential gaps in knowledge that may be needful in addressing the 
main issues in HIV medicine from the gene expression profiles.  
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Abstract 
Background: There is an overwhelming concern regarding the potential toxic effects of highly active 
antiretroviral therapy (HAART) on the renal intracellular milieu. Early detection of this renal damage is 
critical for diagnosis of kidney diseases.  
Aim: The aim of the study is to determine the effect of Momordica charantia (M. charantia) on kidney 
biomarkers Such as neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-
1) and tumor necrosis factor (TNF-α) following HAART in diabetic and non-diabetic rats. 
Materials and Methods: 78 adult male Sprague Dawley rats were divided into two groups (non-diabetic 
and diabetic) and treated according to protocols. Diabetes was induced with streptozotocin (STZ) by 
intraperitoneal injection (45 mg/kg body weight). The animals were euthanized on the tenth week and 
blood obtained via cardiac puncture and centrifuged to collect the sera used for examining NGAL, KIM-1 
and TNF-α.  
Results: Repeated administration of HAART regimen (triplavar) to both the non-diabetic and diabetic 
groups not receiving M. charantia resulted in upregulation of circulating mRNA expression of NGAL, 
KIM-1 and TNF-α, significant at p<0.05. Adjuvant treatment with M. charantia in both non-diabetic and 
diabetic group prevented the upregulation of these kidney injury markers suggesting their potent 
pharmacological properties and attenuating influence. 
Conclusion: The mechanisms whether expression of circulating mRNA expression of these biomarkers 
holds predictive value for nephrotoxicity and diabetic nephropathy warrants further investigations. 
Keywords: HAART; Nephrotoxicity; Diabetes, Kidney; Momordica charantia; Gene expression, 
Sprague-Dawley rats.  
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Introduction 
Highly active antiretroviral therapy (HAART) has been associated with an array of organ toxicities such 
as testicular toxicity, hepatotoxicity, nephrotoxicity and long term complications such as diabetic 
nephropathy even in animal models (Offor et al., 2017, Azu et al., 2016, Azu et al., 2014). Studies from 
our laboratory suggest that nephrotoxicity associated with HAART arise from cumulative mitochondrial 
dysfunction (Offor et al., 2018). Mitochondrial energy generation capacity is subsequently reduced due to 
impairment of oxidative phosphorylation and DNA inhibition within the mitochondrial. This increases 
reactive oxygen species formation and disrupt endothelial homeostasis which later leads to glomerular 
hyperfiltration (Begriche et al., 2011, Newsholme et al., 2007). Several factors may also lead to 
hyperfiltration such as hyperglycemia, and increased glucose reabsorption in the renal tubules. 
Hyperglycemia-mediated oxidative stress plays a key role in the advancement of metabolic disorders such 
as cardiovascular diseases, dyslipidemia and diabetes mellitus (Giri et al., 2018, Alam et al., 2014, Evans 
et al., 2002). 
Plants based adjuvants have been shown to exhibit counter regulatory effects in the process of tissue 
damage and intracellular disruption.  One plant that has received wide recognition for its role in mediating 
in intracellular disruption and pro-inflammatory cytokines suppression is Momordica charantia (M. 
charantia) (Yang et al., 2018, Chao et al., 2014, Bao et al., 2013). M. charantia is an economically 
important medicinal plant belonging to the family Cucurbitaceae and has been used extensively as a 
remedy for a number of diseases and disorders. M. charantia extracts also enhance cellular uptake of 
glucose, promote insulin release and potentiate its effect and increase the number of insulin producing 
beta cells in the pancreas of diabetic animals (Mahmoud et al., 2017, Patel et al., 2012, Singh et al., 2011). 
M. charantia contains three anti-HIV proteins which are alpha- and beta momorcharin, MAP-30 
(Momordica Anti-HIV Protein) and charantin. MAP-30 alpha- and beta-momorcharin inhibit HIV 
replication in acutely and chronically infected cells and thus are considered potential therapeutic agent in 
HIV infection and AIDS (Lim, 2012, Puri et al., 2009). MAP30 antiviral agent is capable of inhibiting 
infection of HIV type 1 (HIV-1) in T lymphocytes and monocytes as well as replication of the virus in 
already-infected cells (Puri et al., 2009). The inhibition of HIV-1 integrase by MAP30 suggests that 
obstruction of viral DNA integration may play a key role in the anti-HIV activity of this protein. 
Gene expression profile plays a pivotal role in the pathogenesis of various kidney diseases, and the degree 
of tubulointerstitial damage is strongly associated with renal prognosis (Ding et al., 2007). Thus, markers 
of kidney injury may be capable of reflecting the degree of sustained renal damage. Neutrophil gelatinase-
associated lipocalin (NGAL), kidney injury molecule (KIM-1) and tumor necrosis factor (TNF-α) are 
established biomarkers that have been reported as early detectors of acute kidney injury. Studies have 
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documented that upregulation of these biomarkers are characterized with tubular epithelial injury, 
interstitial fibrosis and a decline in glomerular filtration rate (GFR) in type 2 diabetic patients (Kishore et 
al., 2017, Sadar et al., 2016, Huang et al., 2014). There is dearth of literature explaining the attenuating 
influence of M. charantia on kidney injury associated with HAART. In this study we detected the 
expression of NGAL, KIM-1 and TNF-α by real time RT-PCR following treatment protocol in diabetic 
and non-diabetic rats.   
Materials and Method 
Materials 
HAART regimen- Triplavar (Cipla-Medpro) containing Lamivudine 150 mg, Nevirapine 400 mg and 
Zidovudine 300 mg, was used for this study. The drug was obtained from Pharmed pharmaceuticals, Pty 
(Ltd) Durban, South Africa. Fifty kilogram of fresh mature unripe fruit of M. charantia was purchased 
from the local Durban market. Samples were authenticated at the herbarium unit of the Department of 
Life Sciences, University of KwaZulu-Natal, Durban, South Africa (voucher no. 4617). 
Preparation of M. charantia fruit ethanolic extract 
The fruits were cleaned, sliced into small pieces and the seeds separated out and discarded. The sliced 
green fruit was first weighed and then dried in shade for approximately 2 weeks. It was then weighed 
again to obtain the final dry weight before pulverizing into a fine power in a commercial grinder and 
stored at 5 
0
C until ready for extraction. The active ingredients were obtained by soxhlet extraction using 
ethanol as the solvent. The solvent was evaporated in a rotary evaporator at 40°−50°C with a percentage 
yield of 85.25%. The wet residue was filtered through a whatman filter and the concentrated extract was 
stored at 4 
0
C ready for use. 
Experimental design 
A total of seventy eight (78) adult male Sprague-Dawley rats weighing 178-232 grams were used for the 
study. Ethical approval was obtained from University of KwaZulu Natal (UKZN) animal research ethics 
committee (AREC) - ethics number AREC/033/016D.  The study was conducted at the Biomedical 
Resource Unit (BRU) of UKZN.   
All rats were housed in well ventilated plastic cages [3 rats per cage for the non-diabetic group (in 12 
cages)] and [3 rats per cage for the diabetic group (in 14 cages)]. The dimensions of cages are (52 cm 
long × 36 cm wide and 24 cm high) and soft wood shavings served as beddings in the cages. Animals 
were maintained under standardized animal house conditions (temperature: 23–25 °C; light: 
approximately 12 h natural light per day) and were fed with standard rat pellets from (Meadow feeds a 
Division of Astral Operations Limited, Durban, South Africa) and given tap water ad libitum. The initial 
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body weight of the animals were recorded before treatment and randomly distributed to non- diabetic 
group (A-F comprising 6 animals per group) and diabetic group (G-L comprising 7 animals per group). 
As shown in the treatment schedules below:  
Non-diabetic group 
Group A served as –ve control  
Group B received HAART regimen (Triplavar)  
Group C received M. charantia (200 mg/kgbw) 
Group D received M. charantia (400 mg/kgbw)  
Group E received Triplavar + M. charantia (200 mg/kgbw)  
Group F received Triplavar + M. charantia (400 mg/kgbw) 
Diabetic group 
Group G served as +ve control  
Group H received HAART regimen (Triplavar)   
Group I received M. charantia (200 mg/kgbw)  
Group J received M. charantia (400 mg/kgbw)  
Group K received Triplavar + M. charantia (200 mg/kgbw)  
Group L received Triplavar + M. charantia (400 mg/kgbw) 
The therapeutic dose of triplavar was adjusted for animal weight using the human therapeutic dose 
equivalent. These substances were administered daily via oral route with orogastric tube. The study lasted 
for 10 weeks. Monitoring of the animals was carried out by the research team. Thereafter, the animals 
were euthanized at the 10
th
 week and the tissues were harvested and prepared for observation. 
Induction of diabetes mellitus    
All rats were placed on a 12 hours fast to obtain baseline fasting blood glucose levels (FBG). The diabetic 
groups were given intra-peritoneal streptozotocin (STZ) (Sigma-Aldrich Chemical Company, Missouri, 
St Louis, USA) at 45 mg/kg body weight dissolved in a citrate buffer (pH 4.5) (Etuk, 2010). Successful 
induction of diabetes was determined by observation of polyuria and polydipsia and confirmed by a 72 
hours post STZ FBG level ≥11 mmol/L. 
Blood sample collection 
Blood was collected in plain tubes via cardiac puncture and allowed to clot. It was then centrifuged at 
3000 revolutions per minute (rpm) for 15 minutes and the serum decanted into Eppendorf tubes and 
stored at –20
o
C pending RNA extraction.  
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RNA extraction and cDNA Synthesis  
RNA was isolated using the Zymo Research Quick-RNA™ Miniprep, CA-USA according manufacturer‘s 
protocol. The iScript cDNA synthesis kit (Bio-Rad, USA) was used to perform reverse transcription (RT). 
Manufactures protocol was followed in preparation of the reagents as well as volumes of reagents used.  
Real –Time Polymerase Chain Reaction (qRT-PCR)   
The ROCHE light cycler SYBR Green I master mix was used to carry out PCR amplifications on 
ROCHE light cycler 96 machine. The Primer sequence used can be found in the table 1 below.  PCR was 
done using the following cycling conditions: Pre-incubation for 10 min at 95 °C, followed by 45 cycles of 
95 °C for 15 s, 60 °C for 30s and 72 °C for 30s. All samples were assayed in duplicate with a positive and 
negative control included in each run. The qRT-PCR results were analysed using the 2
-ΔΔCq
 comparative 
method to compare Cq values of the treated groups to the control group. Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) used to normalise the Cq values of the treated groups and control groups. To 
calculate the fold change, a value of 1 was assigned to the controls (Anier et al., 2010). 
Table 1: Gene primer sequence 
GENE FORWARD REVERSE 
TNF-α 5‘-GACCCTCACACTCAGATCATCCTTCT-3‘ 5‘-ACGCTGGCTCAGCCACTC-3‘ 
KIM-1  
5‘-AACGCA GCG ATT GTG CAT CC-3‘ 
 
5‘ -GTA CAC TCACCA TGG TAA CC-3‘ 
NGAL  
5‘-GAT GAA CTGAAG GAG CGA TTC-3‘ 
 
5‘-TCG GTG GGA ACAGAG AAA AC-3‘ 
GAPDH  
5‘-CCT GGA GAA ACCTGC CAA GTA T-3‘ 
 
5‘-AGC CCA GGA TGC CCT TTA GT-3‘ 
 
 
Statistical Analysis  
Statistical analysis was performed using the GraphPad Prism 5 software (GraphPad, San Diego, CA, 
USA). Student t-test was used to test statistical significance of the obtained data. Results are expressed as 
Mean ± Standard Deviation. In this study, a p-value ≤ 0.05 was considered to be statistically significant.  
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Results 
Circulating TNF-α mRNA expression level in non-diabetic rats 
The circulating TNF-α mRNA expression level in non-diabetic rats showed the triplavar treated group 
had an upregulated TNF-α mRNA level, this is higher than the level in the M. charantia low dose and M. 
charantia high dose groups respectively (p<0.05). The circulating mRNA level in the group treated with 
high dose of M. charantia  did not show any difference when the level was compared with that in the 
group treated with low of dose M. charantia  (p>0.05).  
There was also no significant difference in the circulating level of TNF-α mRNA in the group treated with 
low dose of M. charantia and high dose of M. charantia. Although there was an increase in the TNF-α 
mRNA level in the groups treated with triplavar in combination with M. charantia  (both low and high 
dose) but the levels in these groups respectively was significantly lower than in the group treated with 
only triplavar (p<0.05).  
 
(Bar indicate mean ± SD, a=p<0.05, b= p>0.05) 
Figure 1: Circulating TNF-α mRNA expression level in non-diabetic rats.  
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Circulating TNF-α mRNA expression level in diabetic rats 
The circulating TNF-α mRNA expression level in diabetic rats showed that there was  increase in the 
triplavar treated group, this was significantly higher than the level in the M. charantia low dose treated 
groups and M. charantia  high dose treated groups respectively (p<0.05). The circulating TNF-α mRNA 
level in the group treated with high dose M. charantia was not significantly different from the group 
treated with low dose M. charantia. Co-administration of triplavar and both doses of M. charantia (low 
and high dose) did not show any significant difference in the level of TNF-α mRNA. 
 
 
(Bar indicate mean ± SD, a=p<0.05) 
Figure 2: Circulating TNF-α mRNA expression level in diabetic rats 
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Circulating KIM-1 mRNA expression level in non-diabetic rats 
There was an upregulation in the circulating KIM-1 mRNA level in groups treated with triplavar alone 
and this was significantly higher (p<0.05) when compared with groups treated with concomitant 
administration off triplavar and M. charantia (low and high dose). However, groups treated with low and 
high dose of M. charantia alone did not show any significant change in KIM-1 mRNA levels, as 
compared to control group.  
 
 
(Bar indicate mean ± SD, a=p<0.05) 
Figure 3: Circulating KIM-1 mRNA expression level in non-diabetic rats 
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Circulating KIM-1 mRNA expression level in diabetic rats 
The circulating KIM-1 mRNA expression level in diabetic rats treated with triplavar alone were 
upregulated significantly (p<0.05), and this was higher in comparison with adjuvant treatment of triplavar 
and M. charantia even at the two different doses (low and high dose). There was no difference in the 
circulating KIM-1 mRNA expression levels between animals treated with low dose of M. charantia and 
high dose of M. charantia. There was also a marked decrease in the circulating KIM-1 mRNA expression 
in groups of animals treated with concomitant use of triplavar + M. charantia (200 mg/kgbw and 400 
mg/kgbw) significant at (p>0.05). 
 
 
(Bar indicate mean ± SD, a=p<0.05, b= p>0.05) 
Figure 4: Circulating KIM-1 mRNA expression level in diabetic rats 
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Circulating NGAL mRNA expression level in non-diabetic rats 
The circulating NGAL mRNA expression level in non-diabetic rats showed there was an upregulation in 
animals treated with triplavar alone. This expression was significantly higher (p<0.05) than groups of 
animals treated with combination of triplavar and M. charantia at both low and high dose. The NGAL 
mRNA level in the M. charantia high dose group did not show any significant difference when compared 
with the level in the M. charantia low dose group. There was also no significant difference in the 
circulating NGAL mRNA level between the group treated with triplavar + low dose of M. charantia and 
triplavar + high dose of M. charantia.  
 
 
(Bar indicate mean ± SD, a=p<0.05) 
Figure 5: Circulating NGAL mRNA expression level in non-diabetic rats 
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Circulating NGAL mRNA expression level in diabetic rats 
The circulating NGAL mRNA expression level in diabetic rats showed there was a twofold upregulation 
in the triplavar treated group. The mRNA expression level in the triplavar treated group was significantly 
higher (p<0.05) than the level in the M. charantia low dose, M. charantia high dose  and in the groups 
treated with combination of triplavar and  M. charantia (low and high dose). The NGAL mRNA level in 
the M. charantia high dose group did not significantly differ from the level in the M. charantia low dose 
group. There was a marked increase (p<0.05) in the circulating NGAL mRNA level in the group treated 
with triplavar alone when compared to the level in the group treated with combination of triplavar and 
both doses of M. charantia. 
 
(Bar indicate mean ± SD, a=p<0.05) 
Figure 6: Circulating NGAL mRNA expression level in diabetic rats 
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Discussion 
The present study was designed to assess the value of tissue biomarkers for improved detection of kidney 
injury in rats using HAART as model compound in non-diabetic and diabetic animal model following 
treatment with M. charantia. HAART may accumulate in epithelial tubular cells causing a range of 
effects starting with loss of the brush border in epithelial cells and ending in overt tubular necrosis, 
activation of apoptosis and massive proteolysis (Tiong et al., 2014, Kim and Moon, 2012).  
Our results show that HAART induced renal injury in triplavar treated groups both in non-diabetic and 
diabetic animals as reflected by an upregulation in the circulating NGAL, KIM-1 and TNF-α mRNA 
levels in rat serum. The increased expression of NGAL, KIM-1 and TNF-α in our study agrees with 
(Vaidya et al., 2008) that these three biomarkers reflect renal injury accurately. In a study by (Vaidya et 
al., 2010), changes in gene expression were found to correlate with the progressive histopathological 
alterations with significantly raised levels of traditional clinical parameters, (blood urea nitrogen and 
serum creatinine) indicative of impaired kidney function . These biomarkers are sensitive indicators of 
acute kidney injury caused by exogenous toxicants. Our reports agrees with (Vaidya et al., 2006) that 
changes in the circulating mRNA expression of NGAL and KIM-1 were one of the earliest effects 
observed in kidneys of animals exposed to noxious substances and correlated with the histopathological 
changes in epithelial tubular cells. 
Interestingly, the circulating mRNA expression profiles of these biomarkers (NGAL, KIM-1 and TNF-a) 
were shown to differ considerably following concomitant treatment with M. charantia and HAART and 
M. charantia alone (low and high dose) in both non-diabetic and diabetic animals. The capacity of M. 
charantia treatments to reverse the over expression of the circulating levels of these kidney injury 
markers caused by HAART is an indication of its antioxidative properties. M. charantia possesses 
phytochemical properties which are powerful counter measures against oxidative stress tissue damage. 
Studies have documented the hypoglycemic effects of M. charantia through physiological, 
pharmacological and biochemical mechanisms. It is believed to act via stimulation of peripheral skeletal 
muscle glucose utilization (Kwatra et al., 2016),  inhibition of intestinal glucose uptake (Abas et al., 
2015), inhibition of adipocyte differentiation (Nerurkar et al., 2010), suppression of key gluconeogenic 
enzymes, stimulation of key enzyme of hexose monophosphate (HMP) pathway and preservation of β cell 
islet and its functions (Perumal et al., 2015). 
These three kidney biomarkers (NGAL, KIM-1 and TNF- a) might also provide sensitive endpoints for in 
vivo toxicity. Few studies have investigated the relationship between these biomarkers and diabetes 
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pathogenesis. On the other hand no studies have evaluated the relationship between these markers on 
diabetes pathogenesis following antiretroviral treatment and the role of M. charantia. 
Measuring these circulating expressions of these biomarkers may enable clinicians to make an early 
diagnosis of nephrotoxicity and diabetic nephropathy. Support for this notion comes from numerous 
clinical studies in which plasma KIM-1 and NGAL increased a few hours after induction of nephrotoxic 
drugs (Adiyanti and Loho, 2012).  
Conclusion 
Based on the results assessed in this study, M. charantia fruit extract restored the over expression of the 
circulating levels of these kidney injury markers caused by HAART to a moderate extent. This might be 
due to pronounced antioxidant properties. It is known that the pathogenic pathway for HAART-mediated 
injury has been associated with mitochondrial toxicity. HAART may exert a selective pressure that works 
on the mitochondrial population and destroys mitochondrial that cannot metabolize its components 
eventually resulting to progressive kidney injury. This may initiate a cascade of events starting with 
membrane deterioration, disruption of other energy-dependent process that eventually lead to necrosis and 
upregulation of circulating mRNA expression of NGAL, KIM-1 and TNF-α, as we have observed in our 
study. However, the putative mechanisms whether expression of circulating mRNA expression of these 
biomarkers holds predictive value for nephrotoxicity and diabetic nephropathy warrants further 
investigations. 
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BRIDGING 
BETWEEN CHAPTER FOUR AND CHAPTER FIVE 
As the previous chapters have highlighted the toxicities of HAART both in the non-diabetic and diabetic 
condition looking at the light microscopic observation as well as other biochemical and metabolic 
parameters that were assessed which are actually the first lines of examination following the deleterious 
effects associated with HAART. The next chapter however shed more light on the ultrastructural changes 
that are accompanied with HAART treatment to further potentiate the previous observations. 
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CHAPTER FIVE 
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An ultrastructural investigation of the kidney following treatment with highly active antiretroviral 
therapy and Momordica charantia in non-diabetic and diabetic animals. 
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Abstract 
With the introduction of highly active antiretroviral therapy (HAART) in the management of HIV/AIDS, 
the prognostic indication has shifted the pandemic into a manageable chronic condition. Despite this, 
there is still an unmet medical need on the severe side effects coupled with micro-structural perturbations 
especially in the kidney that have debilitated patients. This study reports ultrastructural changes in the 
kidney following HAART and adjuvant treatment with Momordica charantia in an experimental model. 
Following ethical approval from the University of KwaZulu Natal animal research ethics committee 
(AREC) - ethics number AREC/033/016D, 78 adult male Sprague-Dawley rats were grouped into non-
diabetic and diabetic and diabetes was induced by intraperitoneal injection of STZ (45 mg/kg body 
weight). Animals were treated with M. charantia and HAART regimen (triplavar) according to protocols. 
On day 70, the animals were euthanized with Halothane and kidney tissues were harvested and processed 
for transmission electron microscopy (TEM). 
In the non-diabetic groups, TEM images showed nuclear condensation and mitochondrial distortion 
marked in HAART-alone group compared to others.  
In the diabetic groups, podocytes effacement and membrane disruptions were seen in the diabetic control 
as well as HAART treated group. Glomerular basement membrane surfaces were irregular. Treatment 
with M. charantia alone and as adjuvant with HAART mitigated some of these structural observations 
thus suggesting a protective effect of M. charantia on the kidney. M. charantia extract improved renal 
ultrastructure and reversed HAART-induced ultrastructural alterations.  
Keywords: Highly active antiretroviral therapy, Ultrastructure, Basement membrane, Diabetic 
nephropathy, M. charantia, Sprague-Dawley rats.  
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Introduction 
Reduction in morbidity and mortality has been the most outstanding achievement in the global fight 
against HIV/AIDS in both low and middle-income countries (Günthard et al., 2014, Hayes et al., 2014) 
but despite this achievement, there are concerns about associated side effects of highly active 
antiretroviral therapy (HAART), which have increased more recently (Trickey et al., 2017, Carr and 
Cooper, 2000). HAART- related side effects may be transient or may persist throughout therapy (Takaki 
et al., 2017, Montessori et al., 2004) and have been attributed as a major reason for the discontinuation of 
therapy or change in treatment strategy, thereby limiting patients adherence and consequently, virologic 
effectiveness (Gaida et al., 2016, Günthard et al., 2014). 
HAART related kidney toxicity can present as acute or chronic kidney diseases that lead to changes in 
renal function, inducing metabolic changes and renal damage (Hou and Nast, 2018, Boswell and 
Rossouw, 2017).The pathophysiological mechanisms leading to HAART associated nephrotoxicity 
remains elusive. Although, evidence suggests that HAART nephrotoxicity is linked to mitochondrial 
DNA inhibition which disrupts endothelial homeostasis resulting to endothelial thickening (Milián et al., 
2017, Yedla et al., 2015). Endothelial thickening progresses to arterial hyalinosis which later leads to 
glomerular hyperfiltration (Milián et al., 2017). Several factors may lead to this hyperfiltration such as 
hyperglycemia and increase glucose reabsorption in the renal tubules. This plays a key role in the 
advancement of diabetic nephropathy. (Offor et al., 2018).  
With the heightened attention of nephrotoxicity associated with HAART, management of HIV and AIDS 
has now become a double edge sword with an increased risk of hyperglycemia and insulin resistance. 
Although, it is likely that hyperglycemia in HIV patients undergoing treatment with HAART may be 
accounted for by other pathological conditions linked to HIV infection in interaction with mediating 
processes such as inflammatory cytokines (Brown et al., 2005, Calza et al., 2004). However, in a study by 
(Montessori et al., 2004, Walli et al., 1998),  protease inhibitors (PIs) and non-nucleoside reverse 
transcriptase inhibitors (NNRTIs) medications exacerbated the risk of hyperglycemia and insulin 
resistance. Disturbances in glucose-insulin homeostasis through hyperglycemia and insulin resistance 
predispose to type 2 diabetes mellitus and further microvascular complications of diabetes such as 
diabetic nephropathy (DN). The pathophysiology of DN includes increase in cytokines secretion which 
disrupts endothelial homeostasis with a subsequent decline in glomerular filtration rate (Wada and 
Makino, 2013, Navarro-González et al., 2011).  
Since ancient times, medicinal plants have been a worthy source treating various ailments. One of these 
plants is Momordica charantia (M. charantia), also known as karela, or bitter melon, which belongs to 
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the cucurbitacea family, grows in tropical areas, like east and southern Africa, Asia, and the Caribbean. It 
is cultivated throughout these areas as a food and medicine (Dhiman et al., 2012, Grover and Yadav, 
2004). The M. charantia contains anti-hyperglycemic constituents such as glycosides, saponins, alkaloids, 
fixed oils, triterpenes, proteins and steroids (Grover and Yadav, 2004). Fruit of the M. charantia has 
shown more pronounced anti-hyperglycemic activity. Several studies have reported the anti-diabetic 
effects of M. charantia on renal functional and histological changes in type 2 diabetes mellitus rats 
induced by streptozotocin (Patel et al., 2012, Kumar Shetty et al., 2005). However, there is dearth of 
literature on the antidiabetic effects of M. charantia on the renal changes of rats induced by streptozotocin 
following treatment with HAART. Based on this, this work investigates the adjuvant use of M. charantia 
and antiretroviral therapy in a non-diabetic and diabetic animal model.  
Materials and Methods  
Ethical approval 
Ethical approval was obtained from University of KwaZulu Natal (UKZN) animal research ethics 
committee (AREC) - ethics number AREC/033/016D.  The study was conducted at the Biomedical 
Resource Unit (BRU) of UKZN.   
Materials 
A total of seventy eight (78) adult male Sprague-Dawley rats weighing 178-232 grams were used for the 
study. HAART regimen- Triplavar (Cipla-Medpro) containing Lamivudine 150 mg, Nevirapine 400 mg 
and Zidovudine 300 mg, was used for this study. The drug was obtained from Pharmed pharmaceuticals, 
Pty (Ltd) Durban, South Africa. Fifty kilogram of fresh mature unripe fruit of M. charantia was 
purchased from the local Durban markets. Samples were authenticated at the herbarium unit of the 
Department of Life Sciences, University of KwaZulu-Natal, Durban, South Africa (voucher no. 4617). 
Methods 
Preparation of M. charantia fruit ethanolic extract 
The fruits were cleaned, sliced into small pieces and the seeds separated out and discarded. The sliced 
green fruit was first weighed and then dried in shade for approximately 2 weeks. It was then weighed 
again to obtain the final dry weight before pulverizing into a fine power in a commercial grinder and 
stored at 5 
0
C until ready for extraction. The active ingredients were obtained by soxhlet extraction using 
ethanol as the solvent. The solvent was evaporated in a rotary evaporator at 40°−50°C with a percentage 
yield of 85.25%. The wet residue was filtered through a whatman filter and the concentrated extract was 
stored at 4 
0
C ready for use. 
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Experimental design 
All rats were housed in well ventilated plastic cages [3 rats per cage for the non-diabetic group (in 12 
cages)] and [3 rats per cage for the diabetic group (in 14 cages)]. The dimensions of cages are (52 cm 
long × 36 cm wide and 24 cm high) and soft wood shavings served as beddings in the cages. Animals 
were maintained under standardized animal house conditions (temperature: 23–25 °C; light: 
approximately 12 h natural light per day) and were fed with standard rat pellets from (Meadow feeds a 
Division of Astral Operations Limited, Durban, South Africa) and given tap water ad libitum. The initial 
body weight of the animals were recorded before treatment and randomly distributed to non- diabetic 
group (A-F comprising 6 animals per group) and diabetic group (G-L comprising 7 animals per group). 
As shown in the treatment schedules below:  
Table 1: Showing groups and treatment schedules for non- diabetic animals 
Non- diabetic groups       Treatment 
A -ve control group 
B Triplavar 
C M. charantia (200 mg/kg) 
D M. charantia (400 mg/kg)  
E Traplavar + M. charantia (200 mg/kg) 
F Traplavar + M. charantia (400 mg/kg) 
 
Table 2: Showing groups and treatment schedules for diabetic animals 
 
Diabetic groups Treatment 
G +ve control group 
H Triplavar 
I M. charantia (200 mg/kg) 
J M. charantia (400 mg/kg) 
K Triplavar + M. charantia (200 mg/kg) 
L Triplavar + M. charantia (400 mg/kg) 
 
The therapeutic dose of triplavar was adjusted for animal weight using the human therapeutic dose 
equivalent. These substances were administered daily via oral route with orogastric tube. The study lasted 
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for 10 weeks. Monitoring of the animals was carried out by the research team. Thereafter, the animals 
were euthanized at the 10
th
 week and the tissues were harvested and prepared for observation. 
Induction of diabetes mellitus    
All rats were placed on a 12 hours fast to obtain baseline fasting blood glucose levels (FBG). The diabetic 
groups were given intra-peritoneal streptozotocin (STZ) (Sigma-Aldrich Chemical Company, Missouri, 
St Louis, USA) at 45 mg/kg body weight dissolved in a citrate buffer (pH 4.5) (Etuk, 2010). Successful 
induction of diabetes was determined by observation of polyuria and polydipsia and confirmed by a 72 
hours post STZ FBG level ≥11 mmol/L. 
Tissue preparation for electron microscopy 
Ultrastructure of the kidney was studied using the transmission electron microscope (Tsuno, 2000). To 
accomplish this aim, small samples (about 1 mm) cut from different areas of the kidney were fixed by 
immersion method in formaldehyde-glutaraldehyde mixture at 4°C overnight. Subsequently, the 
specimens were washed (4 x 15 min) in 0.1 M cacodylate buffer (pH 7.2). All samples were post-fixed in 
1% osmium tetroxide for 2 hr. Later, they were washed again (3 x 20 min) in 0.1 M cacodylate buffer (pH 
7.2). After dehydration in a graded series of ethanol (50%, 70%, 90%, 100%) and propylene oxide 
(Merck, Darmstadt, Germany) the specimens were gradually embedded in Spurr‘s Low Viscosity Resin 
(Polysciences, Eppelheim, Germany). Briefly, samples were firstly placed (2 x 15 min) in propylene 
oxide (Merck, Darmstadt, Germany) then in propylene-Spurr‘s resin mixture (2:1) for 1 hr, in propylene-
Spurr‘s resin mixture (1:1) overnight and finally in pure Spurr‘s resin overnight.  
Thereafter, kidney specimens were embedded in silicon molds (Plannet, Wetzlar) containing Spurr‘s resin 
and polymerized at 70°C for 8 hr.  For general morphology, semi-thin sections (1μm) were cut using a 
Leica EM UC7 ultramicrotome (Leica, Germany) and stained with toluidine blue (Sigma-Aldrich 
Chemicals GmbH, Deisenhofen, Germany) for examination under light microscopy. Ultra-thin sections 
were then cut from selected blocks and mounted on copper grids (SSI, Science Services, Munich, 
Germany) and routinely contrasted with uranyl-acetate and lead citrate (Reynolds, 1963) prior to 
examination with a JEOL 2100 HR TEM (JOEL, Japan).  
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Results 
The TEM images shows various ultrastructural features of the kidney. Figure 1A shows intact internal 
lining of the glomerular capsule which is composed of epithelial cells called podocytes covering each 
capillary, forming filtration slits (blue arrows) between interdigitating processes called pedicels (shown in  
fig E and F). Filtrate is produced in the glomerulus when blood plasma is forced under pressure across the 
glomerular basement membrane (GBM) of the glomerular capillary wall and through the filtration slits 
(blue arrows) between the pedicles of podocytes processes.  
Also shown in Fig 1A are intact mesangial cells (MC) in the interstitial and are often stain more darkly. 
The Mesangial cells are enveloped by amorphous mesangail matrix (MM-yellow arrow) surrounding it 
which helps to support capillary loops.  
Figure 1B showed wrinkling and folding of the tubular basement membrane (TBM-green arrow). 
Epithelial cells were markedly hypertrophied. The most striking ultrastructural feature was the finding of 
swollen mitochondrial in the endothelium. The associated swelling of the mitochondrial is an indication 
of degenerative nuclear change. Between the basement membranes of the tubule and the capillary is an 
extension of a fibroblast (F).   
Fig 1 C and D shows important features of the tubules under the TEM. The abundant pinocytotic pits and 
vesicles (V) and the lysosomes (L). These features appear to be intact. Small proteins brought into the 
cells by pinocytosis are degraded in lysosomes and the amino acids released basally. The basolateral sides 
(Fig 1 C and D) are characterized by long invaginating folds of membrane along which many intact long 
mitochondria (MT) are situated. It is suggested that these folds provides an increased surface area for 
pumping of ions across the membrane.  
Figure 1 E and F shows a distinct appearance of the podocytes foot processes or pedicels covering the 
glomerular capillaries. Podocytes have cell bodies which gives rise to several foot processes that embrace 
portions of the glomerular capillary. The pedicels interdigitate, creating elongated spaces called the 
filtration slits. The cell bodies of podocytes are not in contact to the GBM, but rather each pedicel is in 
direct contact with the GBM and this is the most substantial part of the filtration barrier preventing 
macromolecules and other negatively charged molecules from entering the barrier.  
In Fig 1 G and H, the selective permeability of the GBM has been drastically altered indicating an 
increase in thickness of the GBM and podocyte effacement (red arrows). These ultrastructural 
abnormalities were not seen in fig 1 (I, J, K and L) which were treated with either M. charantia and/or its 
combination with HAART. The swollen mitochondria, thickening of GBM and podocytes effacement 
which were major features present in (figure B, G and H) were not conspicuous in other groups.  
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Figure 1.  (A-L): TEM images of the rat kidney (Magnification  2,000,000 x).   
Non diabetic (A-F) (A) –ve Control, (B) HAART alone. (C) M. charantia 200 mg/kg (D) M. charantia 400 mg/kg, (E) M. 
charantia 200 mg/kg + HAART (F) M. charantia 400 mg/kg + HAART.  
Diabetic (G-L) (G) +ve Control (H) HAART alone (I) M. charantia 200 mg/kg (J) M. charantia 400 mg/kg, (K) M. charantia 
200 mg/kg + HAART (L) M. charantia 400 mg/kg + HAART. 
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Discussion 
Our results have shown an improvement in ultrastructural morphology of the kidneys, due to the 
concurrent administration of M. charantia, proving to provide protection against the toxic action of 
HAART. The improved restoration of the ultrastructural morphology of the kidney in the present study 
following concomitant  administration with M. charantia supports our previous studies (Offor et al., 
2018)  under light microscopic observation where M. charantia prevented enlargement of glomerular 
mesangium and tubular damage. From our previous study (Offor et al., 2018), derangements of the 
cytoarchitectural patterns of the kidney were seen as a result of treatment with HAART regimen 
(triplavar). These were characterized by tubular epithelial desquamation and glomerular capillary 
abnormalities with extracellular matrix accumulation (Perazella and Moeckel, 2010, Arendshorst et al., 
1975), which is suggestive that disturbances between the mesangial cell and glomerular capillaries may 
have been drastically altered. Glomerular abnormalities often result in a decrease in surface area available 
for filtration and a consequent decline in glomerular filtration rate and reduction in metabolic activity 
(Fioretto and Mauer, 2007). In diabetic kidney disorder, the glomerular filter is altered as a result of 
weakening basement membrane. This will create permeability to glucose and proteins with the subsequent 
release of protein into the urine.  
In our current study, we found that HAART affects the endothelium by altering its basement membrane. 
Studies have shown that the basement membrane plays an essential role in sustaining the structural and 
functional integrity of the kidney (Miner, 1999). Impairment of the membrane will severely compromise 
the function of the kidney. In the present study, the renal ultrastructure of the HAART-treated rats 
displayed an abnormally, irregular arranged glomerular basement membrane (refer to figure 1G). This 
actually conforms to our previous work and another study indicating that HAART increases carbohydrate 
components and contributes to extensive fibrosis around the basement membrane (Ogedengbe et al., 
2016, Azu et al., 2014). 
As the entire basement membrane is made of extracellular matrix, overexpression or degradation of the 
extracellular matrix will contribute significantly to kidney failure. Accumulation of the extracellular 
matrix is a major cause of interstitial fibrosis, infiltration and a thickened basement membrane that results 
to glomerular abnormalities. Experimental animal studies on HAART have confirmed increased 
infiltration, thickened membrane, extensive necrosis and atrophy with disruption of the normal function 
of the kidney (Wyatt et al., 2009). 
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Antiretroviral drugs have been reported to give rise to several life-threatening complications such as 
mitochondrial dysfunction arising from altered mitochondrial DNA (mtDNA) replication and generation 
of reactive oxygen species (ROS) leading to oxidative stress (Deavall et al., 2012). 
In this study, the damage to mitochondria is probably due to elevated ROS production leading to 
membrane damage with increased permeability to HAART. This is accompanied by disruption of normal 
oxidative phosphorylation and cytoplasmic swelling which eventually results in disruption of cristae, 
collapse of internal mitochondrial structure and energy deprivation (Lewis and Dalakas, 1995). 
Remarkably, M. charantia was found to have protective effects on the kidneys in our study as it 
considerably restored the ultrastructural feature. The beneficial effect of M. charantia on the kidney is 
just a part of various pharmacological properties, particularly its potential as a free radicals scavenger. 
The antioxidant activity of M. charantia extracts mentioned in various studies (Leelaprakash et al., 2011, 
Wu and Ng, 2008, Sathishsekar and Subramanian, 2005), is considered to be exerted mainly by 
flavonoids. Taking into consideration that flavonoids extracted from other medicinal plants with 
renoprotective effects, have been described to inhibit nephrotoxicity induced by xenobiotics in some 
experimental animal models (Renugadevi and Prabu, 2009, Galati and O'brien, 2004). We can suggest 
that the renoprotective effects of M. charantia in our study could be described by a concurrent antioxidant 
and free radicals scavenging effect. This hypothesis is validated by our previous study (Offor et al., 2018) 
where we confirmed that M. charantia extracts was able to re-establish the kidney function of rats 
through its antioxidant activity. 
The ultrastructural abnormalities in the kidney of diabetic rats, including the patchy thickening of the 
basement membrane, were evidently improved by M. charantia treatment. The STZ-induced diabetic rat 
model has been widely used in DN research. In the present study, we successfully established the rat 
model of diabetes according to previous description (King, 2012, Tesch and Allen, 2007). Generally, DN 
is functionally characterized by raised urinary protein and renal dysfunction. In the study by (Dronavalli 
et al., 2008), the DN group exhibited significant increase in renal functional parameters compared to 
control demonstrating that the STZ-induced diabetic rats were subjected to renal dysfunction. Renal 
dysfunction is usually caused by the alterations of structural/cellular basis in DN including extracellular 
matrix accumulation, basement membrane thickening, mesangial cell expansion and podocytes 
hypertrophy (Dronavalli et al., 2008, Ziyadeh, 1993). The present result agrees with (Dronavalli et al., 
2008) that renal dysfunction is associated with renal morphological alterations and M. charantia could 
reduce the risk of renal dysfunction by preventing injuries to the structural/cellular basis. 
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Conclusion  
The current study has shown that the treatment with M. charantia improved the kidney ultrastructural 
features. Our study, according to similar studies, has proven that the ultrastructural kidney alterations 
observed with HAART treatment in non-diabetic and diabetic condition were re-established by M. 
charantia treatment, concluding that M. charantia may have protective effects against morphological 
alterations of the kidneys. We suggest that M. charantia putative mechanisms to unravel the pathways by 
M. charantia could ameliorate/revert kidney abnormalities and other metabolic disorders following 
HAART treatment be explored.  
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CHAPTER SIX 
SYNTHESIS, CONCLUSION AND RECOMMENDATION 
6.1 Synthesis 
The introduction of highly active antiretroviral therapy (HAART) has led to a dramatic reduction in 
morbidity and mortality caused by HIV and AIDS. However, clinicians are increasingly faced with severe 
deleterious consequences associated with HAART which continue to undermine its success. These appear 
to result in damage to mitochondrial DNA mediated via oxidative stress mechanisms (Akay et al., 2014, 
Manda et al., 2011). These adverse effects of HAART which include various metabolic complications and 
multi-organ toxicities arising from long term use have been shown to severely compromise the quality of 
life of people living with HIV and AIDS (PLWHA). Due to cost of HAART majority of those affected 
are unable to afford or continue on these treatments on a consistent and sustainable basis making it 
difficult to meet the WHO plans to reduce the mortality caused by HIV and AIDS globally. Although, 
there has been steady progress in increasing accessibility to ART however, in resource-limited countries 
most patients have no access to this life-saving intervention due to lack of ART centers. Unfortunately, 
the poor and vulnerable segments of society are likely to miss out on accessing HAART (Natrass, 2006). 
The economic burden of sustaining adherence to HAART has posed significant challenges to PLWHA 
leading to settling for traditional remedies (Yang et al., 2018, Hughes et al., 2015). In Africa, traditional 
remedies have been considered a long-established form of health care and a way of life, and many of 
these products are generally safer than potent synthetic pharmaceuticals, locally available and cost-
effective (Hughes et al., 2015). 
Metabolic complications related to long-term exposure to HAART have remained a global problem in the 
management of HIV and AIDS patients. Since   the   introduction of   HAART   in the mid-1990, the  risk 
of diabetes mellitus (DM) have been reported with increasing frequency in PLWHA due to long-term 
exposure to HAART (Lin et al., 2018). The incidence of diabetes mellitus has reached epidemic 
proportions worldwide, and it is expected to increase to over 300 million by 2025. The most frequently 
observed microvascular complications for diabetes mellitus is diabetic nephropathy (DN). DN has 
become an interesting area to researchers especially on the use of traditional herbal medicine to manage a 
chronic condition. 
While the use of herbal products predates the emergence of synthetic therapeutic drugs, its consumption 
in the management of various ailments is a common practice in the African continent (Hughes et al., 
2015). More recently, there has been an increase in the use of herbal products as an adjuvant for people 
living with HIV/AIDS in the era of HAART and this is high among adults in sub-Saharan Africa (Sibanda 
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et al., 2016, Langlois-Klassen et al., 2007). Therefore, this study explores possible protective role of M. 
charantia (traditionally available herbal plant) in the mitigation of HAART‘s effects on the kidney in 
non-diabetic and diabetic animal models with specific focus on histological and ultrastructural alterations, 
gene expression profiles, blood glucose levels and other biochemical changes. 
This study also looked at the organ- body weight changes following the administration of HAART and 
how M. charantia could affect this parameter. Organ-body weight alterations offers significant insight in 
toxicology studies (Azu et al., 2016). The study revealed a significant decrease in body weight of animals 
treated with HAART. Although weight gain may be associated with the initiation of HAART possibly 
due to other metabolic issues related to lipid/sugar, the long term consequence is eventual weight loss 
(Azu et al., 2016). The investigation showed no significant difference in the weight coefficient 
(organ/body weight ratio) of the kidney tissue in the non-diabetic group. However in the diabetic group 
the organ body weight ratios show a significant decreasing trend (p<0.05) for animals treated with 
HAART alone and animals treated with low and high dose of M. charantia alone (Groups C, D and E, 
table 1, chapter 3). 
Nephrotoxicity just like testicular toxicity can manifest in the form of organ hypertrophy. The untreated 
diabetic rats and the diabetic rats treated with HAART displayed a significant increase in kidney weight 
as observed in the study (see table 1, chapter 3). Increase in kidney weight may be attributed to certain 
factors like accumulation of lipid droplets. Accumulation of lipids usually signifies dysfunctional 
mitochondrial and therefore indicates an unhealthy struggling cell and the beginning of necrosis 
(Begriche et al., 2011). Mitochondrial dysfunction may initiate cascade of events starting with membrane 
deterioration, impairment of mitochondrial fatty acid ß-oxidation, oxidative phosphorylation and the 
disruption of other energy-dependent processes that may eventually lead to necrosis of the glomerular 
endothelium. Adjuvant treatment with M. charantia successfully maintained kidney weight in this study.  
Assessment of blood glucose level plays a critical role in evaluating functional capacity of the kidney. 
Elevated levels of blood glucose could occur as a result of occlusion of the vascular wall of the kidney 
(Rask-madsen, and King, 2013). This pathogenic pathway is complex, although it is suggested that there 
is an increase in cytokines secretion and an imbalance of the endogenous vasodilators and constrictors. In 
this study there was significant increase (p<0.05) of the blood glucose levels in animals treated with 
HAART regimen (triplavar) alone which possibly suggest that HAART suppresses glucose utilization by 
tissues. The corresponding increase in blood glucose levels observed resulted to glucose spilling through 
the glomerular filtration apparatus that led to osmotic diuresis. The study also showed that untreated 
diabetic rats and diabetic rats treated with HAART regimen all demonstrated the typical triad of diabetes 
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mellitus (polyuria, polyphagia and polydipsia) as well as elevated blood glucose levels. Interestingly, 
treatment with M. charantia significantly lowered (p<0.05) blood glucose levels in all animals receiving 
M. charantia extract and its concomitant treatment with HAART in both non-diabetic and diabetic 
animals. It is believed that M. charantia extracts exert their blood glucose lowering effects via different 
physiological, pharmacological and biochemical pathways (Singh et al., 2011, Garau et al., 2003, Platel and 
Srinivasan, 1995). Possibly, the mode of action could be stimulation of peripheral and skeletal muscle 
glucose utilization, inhibition of intestinal glucose uptake, inhibition of adipocyte differentiation, 
suppression of key gluconeogenic enzymes, stimulation of key enzyme of HMP pathway, and 
preservation of islet β cells and their functions (Singh et al., 2011, Joseph and Jini, 2013, Nerukar et al., 
2010). We speculate that the mode of action of M. charantia in our study could be by preservation of islet 
β cells and their functions.  
This study also evaluated renal electrolytes (sodium and potassium) and other renal functional indices 
such as albumin, urea, BUN and Scr. These parameters are helpful in understanding kidney function. 
Retention of renal electrolytes (sodium and potassium) can occur due to excessive pressure on the 
nephron and this may eventually lead to organ hypertrophy and a decline in glomerular filtration causing 
leakage of albumin, podocytes effacement and loss of surface area available for filtration (Rask-madsen, 
and King, 2013). In this study, there was leakage of albumin and electrolytes retention in the urine of 
HAART treated animals in non-diabetic and diabetic animals. These functional abnormalities (albumin, 
sodium, potassium, urea) were also present in the urine of untreated diabetic animals which is an 
indication that the glomerular endothelial barrier may have been altered. It is proposed that significant 
pathological glomerular hypertrophy and retention of renal electrolytes is a clear manifestation of 
deranged renal function and this remains the underlying factor for DN.  
Microalbuminuria is a predictor of progression to DN in type 2 diabetes mellitus (T2DM) and is 
associated with an accelerated decline in glomerular filtration rate (El Din et al., 2017). The underlying 
mechanisms for microalbuminuria involves abnormalities of the glomerular endothelial barrier causing 
excessive filtration as well as reduction of renal tubular cell albumin degradation and reabsorption (Tojo 
and Kinugasa, 2012). Urinalysis revealed high concentration of urea in the urine of animals treated with 
HAART both in non-diabetic and diabetic state. Administration of M. charantia alone (low and high 
dose) and its concomitant treatment with HAART restored the urinary metabolites in the non-diabetic and 
diabetic animals studied. 
BUN and Scr are routine indicators to monitor kidney function. These substances are normal metabolic 
waste products that are excreted by the kidneys. In kidney diseases such as diabetic nephropathy or 
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nephrotoxicity, these metabolic waste are not excreted normally and so they accumulate in the body thus 
causing an increase in blood levels of urea and creatinine serum. Accumulation of these metabolic wastes 
in the body eventually affects kidney function. Our study revealed marked impairment in renal function 
with significantly (p<0.05) raised levels of BUN and Scr concentrations in HAART alone treated animals 
(diabetic and non-diabetic) and untreated diabetic animals. The functional capacity of the glomerulus in 
filtration and tubular absorption may have been impaired leading to elevations in levels of BUN and Scr 
concentrations as observed in our study. Adjuvant treatment with M. charantia at both low and high dose 
significantly (p<0.05) restored these kidney function test to near normal by lowering the levels of BUN 
and Scr (chapter 2 table 4 and chapter 3 figure 2).  
It is known that the structural basis of cell is easily destroyed by oxidative stress which has been verified 
to participate in the pathogenesis of nephrotoxicity and diabetic complications, including DN (Hakim and 
Pflueger, 2010). Oxidative stress refers to the imbalance between the antioxidative defense system and the 
oxidative system. It stimulates the excessive production of reactive oxygen species that are toxic to the 
cell, particularly the cell membrane in which these radicals interact with the lipid bilayer and produce 
lipid peroxides (Sharma et al., 2012, Halliwell, 2007). Lipid peroxidation is a metabolic process that 
results in the oxidative degradation of lipids by excess ROS formation leading to attacks by highly 
reactive free radicals. The oxidation of lipid membranes mediates the damage to cell membranes that can 
alter structure and function (Ghosh et al., 2017, Pisoschi and Pop, 2015). This further predisposes cellular 
organelles to functional impairment. Thus, interference with lipid metabolism can seriously compromise 
tissue integrity. Thiobarbituric acid reactive substance (TBARS) is a marker for determining the extent of 
lipid peroxidation in tissues (Ghani et al., 2017). In this study, TBARS levels in the kidney were 
significantly higher in HAART treated group compared to control and other treatment groups. 
Consequently treatment with M. charantia and its adjuvant use with HAART significantly lowered the 
level of TBARS. 
HAART elicits a myriad of mitochondrial alterations which will results in the generation of ROS which 
are the chief arbiters of oxidative stress damage. Mitochondrial alterations due to oxidative stress arising 
from negative interactions of HAART will ultimately cause damage to tissues (Azu, 2012). Endogenous 
antioxidant enzymes (SOD and CAT) and GSH are responsible for the detoxification of deleterious ROS. 
In the present study, the activities of SOD, CAT and levels GSH in the glomeruli of HAART alone 
treated non-diabetic rats and HAART alone treated diabetic rats as well as untreated diabetic rats were 
evidently inhibited along with an increase in MDA levels. By contrast, following M. charantia treatment, 
the activities of all the enzymes displayed a significant increase accompanied with obvious decrease in 
MDA levels. These results demonstrate that M. charantia possesses antioxidant activity and could 
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improve the antioxidative defense system of the kidney. This may be attributed to its high phytochemical 
constituents (e.g. charantin, momordicin) contributing to its antioxidant capacity with a positive 
correlation on other biochemical results that was investigated in this research. 
In this study, significant upregulation of circulating NGAL, KIM-1 and TNF-α mRNA levels were 
detected in the serum following treatment with HAART alone in both non-diabetic and diabetic rats. 
Blockade of the overexpression of these genes could prevent pathological alterations such as extracellular 
matrix (ECM) accumulation and possibly glomerular basement membrane (GBM) thickening (Vaidya et 
al., 2008). The increased expression of the circulating mRNA levels of NGAL, KIM-1 and TNF-α along 
with excessive oxidative stress in the kidney as a result of HAART treatment both in non-diabetic and 
diabetic animals provide evidence that oxidative stress may induce ECM accumulation through 
upregulation of gene expression. When M. charantia was used as an adjuvant with HAART in the 
experimental protocol, circulating NGAL, KIM-1 and TNF-α mRNA levels in the serum decreased, 
accompanied with the reduced oxidative stress and ECM accumulation.  
The histopathological and ultrastructural examinations undertaken in this study reveal morphological 
alterations of the kidney in animals that were administered with HAART alone. Qualitative light 
microscopy data of kidney sections of HAART alone treated (non-diabetic rats) showed derangements of 
the histoarchitecture characterized by tubular epithelial desquamation and glomerular capillary 
abnormalities. There were many indistinguishable tubules, inflammation of the interstitium and extensive 
necrosis. These were findings observed with H&E stains (figure 3B, chapter 2). The PAS and MT 
staining also showed vacuolation of tubules and presence of polysaccharides and collagen fibres (figure 
4B and figure 5B respectively, chapter 2). M. charantia treated groups showed an essentially normal 
glomerular appearance with normal cytoarchitecture comparable to control. 
HAART alone treated (diabetic rats) and untreated diabetic rats showed inflammatory cell infiltrations 
and extracellular matrix accumulation which is suggestive that disturbance between the mesangial cell 
and glomerular capillaries may have been altered. Our study showed obliteration of glomerular capillary 
loops and occlusion of the capillary walls with many indistinguishable tubules, inflammation of the 
interstitial and epithelial desquamation. Cellular inflammation, tubular epithelial damage and severe 
necrosis of the vascular wall characterized by hypercellularity were also observed (see figure 3B and 3C, 
chapter 3). These were key findings in our study. Glomerular abnormalities often result in a decrease in 
surface area available for filtration and a consequent decline in glomerular filtration rate and reduction in 
metabolic activity. 
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Our observations with H and E stains corresponds with PAS and MT staining of the kidney sections 
showing high proportion of carbohydrates such as glycogen and glycoproteins and mild deposition of 
collagen fibers in HAART alone treated (diabetic rats) and untreated diabetic rats (see figure 4B, 4C and 
5B, 5C respectively, chapter 3). The histopathological changes observed in the renal interstitium as a 
result of  HAART in diabetic and non-diabetic rats is an indication that this causes a significant damage to 
the mitochondria most likely due to elevated ROS production. Increase in ROS production is suggested to 
disrupt normal oxidative phosphorylation that will result to cytoplasmic swelling and create an imbalance 
in the intracellular milieu (Ozbek, 2012). M. charantia mitigated these effects with a resultant restoration 
of the kidney histoarchitecture in both low and high dose of M. charantia (diabetic and non-diabetic 
animals). 
The ultrastructural observations obtained also corroborate the light microscopic studies, showing several 
HAART abnormalities such as effacement of the podocytes foot process weakness of the glomerular 
basement membrane. The renal ultrastructure of the HAART- alone treated (non-diabetic) rats showed 
wrinkling and folding of the tubular basement membrane and hypertrophy of epithelial cells. There was 
also swollen mitochondrial in the endothelium (figure 1B, chapter 5). The swelling of the majority of the 
mitochondria seen in the section may suggest change in the permeability of the membrane and depicts and 
unusual degenerative nuclear change (Finsterer and Scorza, 2017). The prime target for HAART is the 
mitochondrial and the hypothesized mechanism is that it reduces the production of ATP that is needed for 
cellular energy. HAART alone treated (diabetic rats) and untreated diabetic rats showed an abnormally 
increased thickness of basement membrane and podocyte effacement which reflects the existence of 
endothelial damage (figure 1G and H, chapter 5). Podocyte effacement as observed in this study is 
thought to be due to a breakdown in the actin cytoskeleton of the foot processes, which is a complex 
contractile apparatus that allows podocytes to be dynamic in nature according to changes in filtration 
requirements (Mathieson, 2012). 
The glomerular basement membrane also plays an essential role in giving structural support to the kidney 
and hence impairment of basement membrane will severely compromise tissue structure (LeBleu et al., 
2007). As the basement membrane is made of extracellular matrix, overexpression or degradation of the 
extracellular matrix will contribute significantly to kidney dysfunction. Accumulation of the extracellular 
matrix is a major cause of interstitial fibrosis, infiltration and a thickened basement membrane that results 
to glomerular abnormalities. The swollen mitochondria, thickening of GBM and podocytes effacement 
which were major features present in figure 1B, G and H, (chapter 5) were not conspicuous in other 
groups treated with M. charantia adjuvant (diabetic and non-diabetic). M. charantia was found to have 
protective effects on the kidneys and may provide a naturally available plant-based adjuvant in ART. 
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6.2 Conclusion 
There is no doubt that the roll out of HAART has been the most important progress in the management of 
HIV in the last two decades and has significantly improved survival of PLWHA. However, its associated 
organ toxicities as well as adverse effects have long been recognized to pose a serious clinical 
management dilemma with dire implications for global health. This calls for a more holistic approach in 
the management of HIV/AIDS; such as adjuvant use of plant-based therapy. 
Results from this study have shown that HAART affected kidney function evidenced by leakage of 
albumin, electrolytes retention and significantly raised levels of BUN and Scr concentrations. This in 
addition to many other derangements as observed in the histological, ultrastructural, molecular and 
biochemical milieu. The use of M. charantia extract mitigates the untoward effects of HAART by 
significantly preserving kidney morphology and enhancing kidney function. In addition, the study has 
shown the worsening effects of HAART in the face of diabetes and the consequences are deleterious.  
6.3 Recommendations    
It is recommended that further studies should be conducted using specific active components of M. 
chanrantia to determine which of the components is responsible for protecting kidney morphology and 
maintaining its function. Precise explanations for the structural changes observed may be better explained 
using stereological techniques for a more detailed quantification. More so, further studies needed to be 
carried out using additional doses to ascertain if the protective effect of M. charantia is dose dependent 
that way an appropriate dose can be established. 
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